Methods and compositions for treating premature stop codon-mediated disorders
Patent Information
- Application Number
- JP2022526004
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-11-01
- Filing Date
- 2020-10-30
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2040-10-30
AI Technical Summary
Current methods are inadequate for effectively treating disorders caused by premature stop codons, such as Dravet syndrome, which result from nonsense mutations leading to non-functional proteins.
The use of suppressor tRNAs that incorporate amino acids at premature stop codons within genes, allowing for the production of full-length functional proteins, using modified tRNAs and expression vectors to introduce these tRNAs into mammalian cells.
This approach enables the expression of functional gene products, increasing voltage-gated sodium channel activity and potentially treating disorders like Dravet syndrome by restoring protein function.
Smart Images

Figure 00000161_0000 
Figure 00000161_0001 
Figure 00000161_0002
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims the benefits and priority of U.S. Provisional Patent Application No. 62 / 929,428, filed on November 1, 2019, which is incorporated herein by reference in its entirety for all purposes.
[0002] Field of Invention The present invention generally relates to methods and compositions for expressing gene products encoded by genes containing immature stop codons, and / or for addressing disorders mediated by immature stop codons. [Background technology]
[0003] background Protein synthesis is driven by a genetic code that includes 61 three-base pair codons that code for the amino acids incorporated into the synthesized protein, and three three-base pair codons (called stop codons) that terminate protein synthesis. When the nucleic acid sequence coding for a protein mutates to contain an immature stop codon instead of a codon for the next amino acid, the resulting protein terminates at an immature stage, which is often non-functional or less functional than a truncated or full-length protein. Such mutations, called nonsense mutations, are often associated with or causative of many different genetic disorders.
[0004] Many disorders are associated with or caused by nonsense mutations. These include epilepsy, such as Dravet syndrome, hereditary epilepsy with febrile seizures (GEFS), benign familial infantile epilepsy (BFIE), early infantile epileptic encephalopathy (EIEE), Lennox-Gastaut syndrome, Rett syndrome, PPM-X syndrome, Ohtahara syndrome, recurrent paroxysmal ataxia, hemiplegic migraine, idiopathic generalized epilepsy, FOXG1 syndrome, familial focal epilepsy with multiple foci (FFEVF), childhood-onset epileptic encephalopathy, and SYNGAP. This includes 1-related intellectual disability, pyridoxine-dependent epilepsy, familial infantile myoclonic epilepsy (FIME), myoclonic ataxia, X-linked intellectual disability, partial epilepsy and recurrent paroxysmal ataxia, febrile seizures, autosomal dominant partial epilepsy with auditory symptoms (ADPEAF), PNPO deficiency, progressive myoclonic epilepsy, action myoclonus-renal failure (AMRF), CDKL5 deficiency disorder, and benign familial infantile seizures (BFIS).
[0005] For example, Dravet syndrome is a rare and devastating form of intractable epilepsy that begins in infancy. Initially, patients experience prolonged seizures. In the second year, further types of seizures begin to occur, accompanied by developmental delays, typically due to recurrent cerebral hypoxia. This results in insufficient development of language and motor skills. Mutations in the SCN1A (encoding the α subunit of the voltage-opening sodium channel Nav1.1), SCN1B (encoding the β1 subunit of the voltage-opening sodium channel), SCN2A (encoding Nav1.2), SCN3A (encoding Nav1.3), SCN9A (encoding Nav1.7), GABRG2 (encoding the γ2 subunit of the γ-aminobutyric acid receptor), GABRD (encoding the Δ subunit of the γ-aminobutyric acid receptor), and / or PCDH19 (encoding protocadherin-19) genes are associated with Dravet syndrome.
[0006] Dravet syndrome can be caused by nonsense mutations in the SCN1A gene, such as those resulting in immature stop codons and the absence or reduction of non-truncate or functional proteins. The SCN1A gene normally encodes Na(V)1.1, the α subunit of the neuronal voltage-opening sodium channel. In mouse models, loss-of-function mutations in SCN1A have been observed to result in decreased sodium flow and impaired excitability of GABAergic interneurons in the hippocampus.
[0007] Despite the efforts made to date, there is a need in the art for improved compositions and methods for treating diseases mediated by immature stop codons, including Dravet syndrome. [Overview of the Initiative]
[0008] The present invention is based in part on the discovery of tRNAs (e.g., suppressor tRNAs) that enable the insertion of amino acids into a gene product encoded by a certain gene in mammalian cells at a site where a truncated gene product would otherwise result due to an immature stop codon (PTC) within that gene. The present invention is further based in part on the discovery that tRNAs that enable the insertion of amino acids into a gene product encoded by a certain gene at a site where a truncated gene product would otherwise result due to a PTC within that gene, such as the tRNAs described herein, can be used in subjects to treat diseases mediated by PTCs within a certain gene.
[0009] Therefore, in one aspect, the present invention provides tRNAs comprising the nucleotide sequences shown in Table 2. In a particular embodiment, the tRNA comprises nucleotide sequences selected from SEQ ID NO: 19-21, 37, 39, 40, 44, 179, 181, 182, and 186.
[0010] In certain embodiments, the tRNA includes one or more intrinsic nucleotide modifications selected from, for example, 5-methyluridine, 5-carbamoylmethyluridine, 5-carbamoyl-methyl-2-O-methyluridine, 5-methoxy-carbonylmethyluridine, 5-methoxycarbonylmethyl-2-thiouridine, pseudouridine, dihydrouridine, 1-methyladenosine, and inosine.
[0011] In another aspect, the present invention provides an expression vector comprising a nucleotide sequence encoding any of the above-mentioned tRNAs. In a particular embodiment, the expression vector comprises the nucleotide sequence encoding the tRNA in 1, 2, 3, 4, or more than 4 copies. In a particular embodiment, the expression vector comprises a nucleotide sequence corresponding to a genomic DNA sequence adjacent to the wild-type tRNA gene. For example, in a particular embodiment, the expression vector comprises the nucleotide sequences shown in Table 4. In a particular embodiment, the nucleotide sequences shown in Table 4 are selected from SEQ ID NO: 869 to 888. In a particular embodiment, the nucleotide sequences shown in Table 4 are functionally ligated to the nucleotide sequence encoding the tRNA. In a particular embodiment, within the expression vector, the nucleotide sequences shown in Table 4 are 5' to the nucleotide sequence encoding the tRNA. In a particular embodiment, within the expression vector, the nucleotide sequences shown in Table 4 are immediately 5' to (i.e., adjacent to) the nucleotide sequence encoding the tRNA.
[0012] In another aspect, the present invention provides an expression vector containing nucleotide sequences encoding tRNA shown in Table 3 in 1, 2, 3, 4, or more than 4 copies. In a particular embodiment, the tRNA comprises nucleotide sequences selected from SEQ ID NO: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187.
[0013] In another aspect, the present invention provides an expression vector comprising a nucleotide sequence encoding a tRNA shown in Table 3, further comprising a nucleotide sequence shown in Table 4. In a particular embodiment, the tRNA comprises a nucleotide sequence selected from SEQ ID NO: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187. In a particular embodiment, the nucleotide sequence shown in Table 4 is selected from SEQ ID NO: 869-888. In a particular embodiment, the nucleotide sequence shown in Table 4 is functionally ligated to the nucleotide sequence encoding the tRNA. In a particular embodiment, within the expression vector, the nucleotide sequence shown in Table 4 is 5' to the nucleotide sequence encoding the tRNA. In a particular embodiment, within the expression vector, the nucleotide sequence shown in Table 4 is immediately 5' to the nucleotide sequence encoding the tRNA (i.e., adjacent).
[0014] In any particular embodiment of the expression vector described above, the expression vector is a viral vector, such as a DNA viral vector, such as an adeno-associated virus (AAV) vector.
[0015] In another aspect, the present invention provides a pharmaceutical composition comprising any of the above-mentioned tRNAs or expression vectors and a pharmaceutically acceptable excipient. In certain embodiments, the tRNA or expression vector is neither conjugated nor bound to another part, such as a carrier particle, such as an aminolipid particle. In certain embodiments, the composition does not contain nanoparticles and / or aminolipid delivery compounds.
[0016] In another aspect, the present invention provides a method for expressing a functional gene product encoded by a gene containing an immature stop codon in mammalian cells, the method comprising the step of introducing an effective amount of either the tRNA or expression vector into cells, thereby enabling the incorporation of an amino acid into the gene product at a position in the gene product where a truncated gene product would otherwise result due to the immature stop codon. In any particular embodiment of the above method, the gene is selected from the genes shown in Table 5 or Table 6. In a particular embodiment, the gene is the SCN1A gene.
[0017] In another aspect, the present invention provides a method for expressing a functional gene product encoded by a gene containing an immature stop codon in mammalian cells, the method comprising the steps of introducing into cells an effective amount of tRNA shown in Table 3 (e.g., tRNA containing a nucleotide sequence selected from SEQ ID NO: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187) or an expression vector containing a nucleotide sequence encoding said tRNA, thereby enabling the incorporation of an amino acid in the gene product at a position in the gene product where a truncated gene product would otherwise result due to an immature stop codon, the gene being the gene shown in Table 5. In a particular embodiment, the gene is the SCN1A gene.
[0018] In any particular aspect of the above method, the cells contain fewer truncated gene products than cells lacking the tRNA. In any particular aspect, the cells contain more functional gene products than cells lacking the tRNA.
[0019] In another aspect, the present invention provides a method for increasing the activity of a voltage-opening sodium channel encoded by the SCN1A gene containing an immature stop codon in a cell, the method comprising the steps of introducing an effective amount of either of the above tRNAs or either of the above expression vectors into a cell, thereby enabling the incorporation of an amino acid into the SCN1A gene product at a position in the SCN1A gene product where a shortened SCN1A gene product would otherwise result due to the immature stop codon.
[0020] In another aspect, the present invention provides a method for increasing the activity of a voltage-opening sodium channel encoded by the SCN1A gene containing an immature stop codon in cells, the method comprising introducing into cells an effective amount of tRNA shown in Table 3 (e.g., tRNA containing a nucleotide sequence selected from SEQ ID NO: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187) or an expression vector containing a nucleotide sequence encoding said tRNA, thereby enabling the incorporation of an amino acid into the SCN1A gene product at a position in the SCN1A gene product where a truncated SCN1A gene product would otherwise result due to an immature stop codon.
[0021] In any particular embodiment of the above method, in which the gene is the SCN1A gene, the SCN1A gene product produced by the tRNA is a functional SCN1A gene product. In a particular embodiment, the functional SCN1A gene product has higher activity than the truncated SCN1A gene product. In a particular embodiment, the functional SCN1A gene product is Na v 1.1 It is a protein. In a particular embodiment, the functional SCN1A gene product contains one amino acid sequence from SEQ ID NO: 863 to 868.
[0022] In any particular embodiment of the above method, the cells are human cells. In a particular embodiment, the cells are central nervous system cells, such as neurons. In a particular embodiment, tRNA is aminoacylated within the cell.
[0023] In another aspect, the present invention provides a method for treating an immature stop codon-mediated disorder in a subject that has a gene having an immature stop codon, the method comprising the step of administering an effective amount of any of the above tRNAs or any of the above expression vectors to the subject, thereby treating the disorder in the subject. In a particular embodiment, the disorder is selected from the disorders shown in Table 5 or Table 6.
[0024] In another aspect, the present invention provides a method for treating an immature stop codon-mediated disorder in a subject that needs to treat the disorder, wherein the subject has a gene having an immature stop codon, and the method comprises the steps of administering to the subject an effective amount of tRNA shown in Table 3 (e.g., tRNA containing a nucleotide sequence selected from SEQ ID NO: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187) or an expression vector containing a nucleotide sequence encoding the tRNA, thereby treating the disorder in the subject, wherein the disorder is one of those shown in Table 5.
[0025] In any particular embodiment of the above treatment method, the disorder is epilepsy, for example, Dravet syndrome. In a particular embodiment, the subject is a human. In a particular embodiment, the method further includes the step of administering an effective amount of another drug, for example DIACOMIT® (stiripentol), EPIODOLEX® (cannabidiol), a ketogenic diet, ONFI® (clobazam), TOPAMAX® (topiramate), fenfluramine, or valproic acid to the subject.
[0026] In any particular aspect of the above method, where the gene is the SCN1A gene, the immature stop codon within the SCN1A gene is brought about by a mutation or combination of mutations selected from c.664C>T, c.1129C>T, c.1492A>T, c.1624C>T, c.1738C>T, c.1837C>T, c.2134C>T, c.2593C>T, c.3637C>T, c.3733C>T, c.3985C>T, c.4573C>T, c.5656C>T, and c.5734C>T. In a particular aspect, the immature stop codon is brought about by a mutation selected from c.1738C>T and c.3985C>T.
[0027] These and other aspects and features of the present invention are described in the following detailed description and claims. [Brief explanation of the drawing]
[0028] This invention can be more fully understood by referring to the following drawings.
[0029] (Figure 1) This is a schematic diagram of a transcript containing an immature stop codon (PTC) that results in a shortened protein product (e.g., a protein product in a subject with Dravet syndrome) (e.g., an SCN1A transcript). Native stop codons are shown as shaded circles, and immature stop codons are shown as unshaded circles. Expression of a suppressor tRNA loaded with its congener amino acid (AA) (e.g., anticodon-modified arginine tRNA) enables PTC read-through and promotes the expression of the full-length protein. (Figure 2A) This is the common tRNA secondary structure. The residue numbers are based on the tRNA numbering system described in Steinberg et al. (1993) NUCLEIC ACIDS RES. 21:3011-15. (Figure 2B) This table shows the modification profiles of tRNA sequences derived from the cytosol of specific eukaryotes. The ratios in the table indicate the frequency of occurrence of the listed nucleotides at the positions indicated by the numbers in Figure 2A. The abbreviations for modified residues are defined in Motorin et al. (2005) “Transfer RNA Modification,” ENCYCLOPEDIA OF LIFE SCIENCES, John Wily & Sons, Inc. (Figure 3) This is a schematic diagram of a bifluorescence reporter construct containing three copies of red fluorescent protein (tdTomato), a TEV protease, a 51 bp linker region containing the PTC+ / -8 adjacent codon, and three copies of green fluorescent protein (EGFP). Expression is promoted by the promoter of the elongation factor EF-1α located upstream of the first copy of tdTomato. The tdTomato, the full copies of EGFP, and the TEV protease are separated from each other by the TEV protease cleavage site (Glu-Asn-Leu-Tyr-Phe-Gln-(Gly / Ser)). (Figure 4) In the Flp-In-293 cell line, which stably expresses a bifluorescent reporter containing a target S-PTC linker region (SEQ ID NO: 29) derived from a clinically relevant SCN1A nonsense mutation associated with Dravet syndrome, Arg TCA This graph shows the read-through activity of suppressor tRNA. TCASuppressor tRNAs (SEQ ID NO: 1-25 and 35) were transfected into cells, and readthrough activity was measured by flow cytometry in two independent experiments 24 hours after transfection. "Parent" refers to the original Flp-In-293 cell line without the fluorescent reporter; "No PTC" refers to Flp-In-293 cell lines stably expressing a bifluorescent reporter with a PTC-less version of the target S-PTC linker region (SEQ ID NO: 194); "EV" (empty vector) refers to cells transfected with an expression construct without tRNA; and "TCG" refers to cells transfected with an expression construct containing wild-type Arg-tRNA with a TCG anticodon. Readthrough activity is expressed as the percentage of viable cells expressing both tdTomato and EGFP beyond the background ("Double Positive %"). Error bars represent the standard deviation of the data. (Figure 5) In Flp-In-3T3 cell lines that stably express a bifluorescent reporter containing the R1407X-PTC linker region (SEQ ID NO: 30) derived from a clinically relevant SCN1A nonsense mutation associated with Dravet syndrome, Arg TCA This graph shows the read-through activity of suppressor tRNA. TCASuppressor tRNAs (SEQ ID NO: 1-25) were transfected into cells, and readthrough activity was measured by flow cytometry in three independent experiments 24 hours after transfection. "Parent" refers to the original 3T3 cell line without the fluorescent reporter; "No PTC" refers to a 3T3 cell line stably expressing a bifluorescent reporter with a PTC-less version of the R1407X-PTC linker region (SEQ ID NO: 195); "Mock" refers to mock-transfected cells; "EV" (empty vector) refers to cells transfected with an expression construct containing neither tRNA nor the EGFP reporter; and "TCG" refers to cells transfected with an expression construct containing wild-type Arg-tRNA with the TCG anticodon. Readthrough activity is expressed as the percentage of viable cells expressing both tdTomato and EGFP beyond the background ("Double Positive %"). Error bars represent the standard deviation of the data. (Figure 6) Arg in Flp-In-3T3 cells transiently expressing a bifluorescent reporter containing a target N-PTC linker region (SEQ ID NO: 28) derived from a clinically relevant SCN1A nonsense mutation associated with Dravet syndrome. TCA This graph shows the read-through activity of suppressor tRNA. TCA Suppressor tRNAs (SEQ ID NO: 1-25 and 35) were co-transfected into cells, and readthrough activity was measured by flow cytometry. "Mock" indicates mock-transfected cells, "No PTC" indicates cells transfected with a bifluorescent reporter containing a PTC-less version of the target N-PTC linker region (SEQ ID NO: 193), "EV" (empty vector) indicates cells co-transfected with an expression construct that does not contain tRNA, and "TCG" indicates cells co-transfected with an expression construct containing wild-type Arg-tRNA with a TCG anticodon. Readthrough activity was measured by flow cytometry and expressed as the percentage of viable cells expressing both tdTomato and EGFP beyond the background ("double-positive %"). (Figure 7) Graph showing the readthrough activity of the indicated Arg TCA suppressor tRNAs (measured by the percentage of positive GFP cells) in Neuro-2a (N2a) and Flp-In-293 (293) cells. An expression construct containing the EGFP-R96X-TGA reporter (SEQ ID NO:31) was co-transfected into cells with an expression construct containing the indicated Arg TCA suppressor tRNAs (SEQ ID NOs: 1-22). "EGFP" indicates cells transfected with a version of the EGFP reporter lacking a PTC, and "EGFP-PTC" indicates cells transfected with the EGFP-R96X-TGA reporter alone. EGFP expression was analyzed by flow cytometry approximately 24 hours after transfection in 293 cells and approximately 48 hours after transfection in N2a cells. Readthrough activity is represented as the ratio of viable cells expressing EGFP above background ("GFP+%"), and all values are normalized to cells expressing EGFP lacking a PTC. (Figure 8A) Schematic of the experimental approach for measuring suppressor tRNA activity using constructs containing an EGFP reporter with a PTC and suppressor tRNAs. Native stop codons are indicated by shaded circles, and premature stop codons are indicated by unshaded circles. Standard Arg-tRNA (containing an anticodon that binds to CGA) cannot read through the PTC in EGFP, resulting in a non-functional truncated EGFP protein. Suppressor tRNA (containing an anticodon that binds to UGA) enables readthrough of the PTC in EGFP, resulting in a full-length functional EGFP protein. (Figure 8B) Schematic of an exemplary reporter construct containing EGFP with a PTC and 4 copies of suppressor tRNA. (Figure 9) EGFP-R96X-TGA reporter (SEQ ID NO:31) and the indicated number of copies of the indicated Arg TCAThe images show fluorescence images of Neuro-2a cells transfected with expression constructs containing suppressor tRNAs. The suppressor tRNAs are TCA-001 (SEQ ID NO: 11), TCA-113 (SEQ ID NO: 16), and TCA-115 (SEQ ID NO: 18). Each copy of suppressor tRNA also contains 200 bp upstream flanking genomic DNA (SEQ ID NO: 26) and 104 bp downstream flanking genomic DNA (SEQ ID NO: 32) derived from tRNA-Arg-TCG-1-1. The images were taken approximately 24 hours after transfection. GFP controls are shown from left to right: 1) wild-type EGFP alone, and 2) a single copy of Arg. TCA The three expressions are: 1) wild-type EGFP on an expression construct containing suppressor tRNA #001 (SEQ ID NO: 11), 2) EGFP-R96X-TGA reporter alone, and 3) EGFP-R96X-TGA on an expression construct containing four copies of Arg-tRNA with unmodified TCG anticodons. (Figure 10) EGFP-R96X-TGA reporter (SEQ ID NO: 31) and the indicated copy number, indicated Arg TCA The images show fluorescence images of Flp-In-293 cells transfected with expression constructs containing suppressor tRNAs. The suppressor tRNAs are TCA-001 (SEQ ID NO: 11), TCA-113 (SEQ ID NO: 16), and TCA-115 (SEQ ID NO: 18). Each copy of suppressor tRNA also contained 200 bp upstream flanking genomic DNA (SEQ ID NO: 26) and 104 bp downstream flanking genomic DNA (SEQ ID NO: 32) from tRNA-Arg-TCG-1-1. The images were taken approximately 48 hours after transfection. GFP controls are shown from left to right: 1) wild-type EGFP alone, and 2) a single copy of Arg. TCAThe three expressions are: 1) wild-type EGFP on an expression construct containing suppressor tRNA #001 (SEQ ID NO: 11), 2) EGFP-R96X-TGA reporter alone, and 3) EGFP-R96X-TGA on an expression construct containing four copies of Arg-tRNA with unmodified TCG anticodons. (Figure 11) EGFP-R96X-TGA reporter (SEQ ID NO: 177) and Arg TCA The fluorescence measured by flow cytometry is shown in Neuro-2a and Flp-In-293 cells transfected with an expression construct containing suppressor tRNA #001 (SEQ ID NO: 11). The expression construct contained 1 (1x), 2 (2x), or 4 (4x) copies of suppressor tRNA under either the following chronological order: (i) a U6 promoter ("U6") containing 19 bp upstream neighboring genomic DNA (SEQ ID NO: 33) and 46 bp downstream neighboring genomic DNA (SEQ ID NO: 34) from tRNA-Arg-TCG-1-1, or (ii) 200 bp upstream neighboring genomic DNA (SEQ ID NO: 26) and 200 bp downstream neighboring genomic DNA (SEQ ID NO: 27) ("neighboring") from tRNA-Arg-TCG-1-1. "Empty vector" refers to cells transfected with an expression construct that contains neither tRNA nor the EGFP reporter, while "EF1a:EGFP" refers to cells transfected with a PTC-less version of the EGFP reporter. Analysis was performed approximately 48 hours after transfection. The data are presented as a histogram showing the frequency distribution of the data against fluorescence intensity in viable cells expressing EGFP above the background. (Figure 12) Under either the following sequence: (i) a U6 promoter ("U6") containing a 19 bp upstream neighboring genomic DNA (SEQ ID NO: 33) derived from tRNA-Arg-TCG-1-1 and a 46 bp downstream neighboring genomic DNA (SEQ ID NO: 34) derived from tRNA-Arg-TCG-1-1, or (ii) a 200 bp upstream neighboring genomic DNA (SEQ ID NO: 26) derived from tRNA-Arg-TCG-1-1 and a 200 bp downstream neighboring genomic DNA (SEQ ID NO: 27) derived from tRNA-Arg-TCG-1-1 ("neighboring"), the EGFP-R96X-TGA reporter (SEQ ID NO: 177) and the Arg of the indicated copy number. TCA This figure shows the percentage of EGFP-positive cells and mean EGFP intensity in all viable cells, as measured by flow cytometry, in Neuro-2a cells transfected with an expression construct containing suppressor tRNA #001 (SEQ ID NO: 11). "Empty vector" indicates cells transfected with an expression construct containing neither tRNA nor the EGFP reporter, while "EF1a:EGFP" indicates cells transfected with a PTC-less version of the EGFP reporter. Analysis was performed approximately 48 hours after transfection. These plots summarize the data from Neuro-2a cells in Figure 11. (Figure 13) EGFP-R96X-TGA reporter (SEQ ID NO:31) and Arg TCAThe images show fluorescence measured by flow cytometry in Neuro-2a cells transfected with an expression construct containing suppressor tRNA #001 (SEQ ID NO: 11). The expression construct contained 1 (1x), 2 (2x), 3 (3x), or 4 (4x) copies of suppressor tRNA. Each copy of suppressor tRNA also contained 200 bp upstream flanking genomic DNA (SEQ ID NO: 26) and 104 bp downstream flanking genomic DNA (SEQ ID NO: 32) derived from tRNA-Arg-TCG-1-1 ("flanking"). "CAG:EGFP" indicates cells transfected with a PTC-less version of the EGFP reporter, and "Mock" indicates cells transfected with the EGFP-R96X-TGA reporter alone. Analysis was performed approximately 48 hours after transfection. The data is presented as a histogram showing the frequency distribution of the data against fluorescence intensity in all viable cells ("G1 gate") and viable cells expressing EGFP above the background level ("GFP+ gate"). (Figure 14) EGFP-R96X-TGA reporter (SEQ ID NO:31) and Arg TCAThe images show fluorescence measured by flow cytometry in Neuro-2a cells transfected with an expression construct containing suppressor tRNA #113 (SEQ ID NO: 16). The expression construct contained 1(1x), 2(2x), 3(3x), or 4(4x) copies of suppressor tRNA. Each copy of suppressor tRNA also contained 200 bp upstream flanking genomic DNA (SEQ ID NO: 26) and 104 bp downstream flanking genomic DNA (SEQ ID NO: 32) derived from tRNA-Arg-TCG-1-1 ("flanking"). "CAG:EGFP" indicates cells transfected with a PTC-less version of the EGFP reporter, while "Mock" indicates cells transfected with the EGFP-PTC reporter alone. Analysis was performed approximately 48 hours after transfection. The data is presented as a histogram showing the frequency distribution of the data against fluorescence intensity in all viable cells ("G1 gate") and viable cells expressing EGFP above the background level ("GFP+ gate"). (Figure 15) EGFP-R96X-TGA reporter (SEQ ID NO:31) and Arg TCAThe fluorescence measured by flow cytometry is shown in Neuro-2a cells transfected with an expression construct containing suppressor tRNA #115 (SEQ ID NO: 18). The expression construct contained 1 (1x), 2 (2x), 3 (3x), or 4 (4x) copies of suppressor tRNA. Each copy of suppressor tRNA also contained 200 bp upstream flanking genomic DNA (SEQ ID NO: 26) and 104 bp downstream flanking genomic DNA (SEQ ID NO: 32) from tRNA-Arg-TCG-1-1 ("flanking"). "CAG:EGFP" indicates cells transfected with a PTC-less version of the EGFP reporter, and "Mock" indicates cells transfected with the EGFP-R96X-TGA reporter alone. Analysis was performed approximately 48 hours after transfection. The data is presented as a histogram showing the frequency distribution of the data against fluorescence intensity in all viable cells ("G1 gate") and viable cells expressing EGFP above the background level ("GFP+ gate"). (Figure 16) This figure shows the percentage of EGFP-positive cells in all viable cells ("GFP+ cells %") and the mean EGFP intensity in EGFP-positive cells ("GFP+ gated"), measured by flow cytometry, in Neuro-2a cells transfected with an expression construct containing the EGFP-R96X-TGA reporter (SEQ ID NO: 31) and the indicated copy numbers of the indicated suppressor tRNAs. The suppressor tRNAs are TCA-001 (SEQ ID NO: 11), TCA-113 (SEQ ID NO: 16), and TCA-115 (SEQ ID NO: 18). "CAG:EGFP" indicates cells transfected with the EGFP reporter without PTC, and "CAG:EGFP-PTC" indicates cells transfected with the EGFP-R96X-TGA reporter alone. These plots summarize the data from Figures 13–15. (Figure 17) EGFP-R96X-TGA reporter (SEQ ID NO: 31) and the shown Arg with the shown copy number and adjacent sequence. TCA This shows the percentage of EGFP-positive cells, as measured by flow cytometry, in Neuro-2a cells transfected with expression constructs containing suppressor tRNAs. The suppressor tRNAs are TCA-001 (SEQ ID NO: 11), TCA-113 (SEQ ID NO: 16), and TCA-115 (SEQ ID NO: 18). "U6" indicates the U6 promoter containing 19 bp upstream neighboring genomic DNA (SEQ ID NO: 33) and 46 bp downstream neighboring genomic DNA (SEQ ID NO: 34) derived from tRNA-Arg-TCG-1-1; "Neighboring (±200 bp)" indicates 200 bp upstream neighboring genomic DNA (SEQ ID NO: 26) and 200 bp downstream neighboring genomic DNA (SEQ ID NO: 27) derived from tRNA-Arg-TCG-1-1; and "Neighboring (+200 / -100 bp)" indicates 200 bp upstream neighboring genomic DNA (SEQ ID NO: 26) and 104 bp downstream neighboring genomic DNA (SEQ ID NO: 32) derived from tRNA-Arg-TCG-1-1 ("Neighboring"). "Mock" indicates mock-transfected cells; "Empty Vector" indicates cells transfected with an expression construct containing neither tRNA nor the EGFP reporter; "4xTCG" indicates cells transfected with an expression construct containing the EGFP-R96X-TGA reporter and four copies of wild-type Arg-tRNA with the TCG anticodon; and "CAG:EGFP" indicates cells transfected with a PTC-less version of the EGFP reporter. All data are normalized to the positive control (CAG:EGFP). The plots show the percentage of viable cells expressing GFP above the background. (Figure 18) Dmd derived from clinically relevant DMD nonsense mutations associated with Duchenne muscular dystrophy. mdx- In two separately obtained Flp-In-293 cell lines (#2 and #10) that stably express a bifluorescent reporter having a PTC linker region (SEQ ID NO:192), Gln TTA This graph shows the read-through activity of suppressor tRNA. TTA Suppressor tRNAs (SEQ ID NO: 36-48) were transfected into cells, and readthrough activity was measured by flow cytometry 24 hours after transfection. "Parent" refers to the original Flp-In-293 cell line without a fluorescent reporter, and "No PTC" refers to a version of Dmd lacking a PTC. mdx -The cell line is Flp-In-293, which stably expresses a bifluorescent reporter having a PTC linker region (SEQ ID NO:191). "TTG" indicates cells transfected with an expression construct containing wild-type Gln-tRNA with the TTG anticodon. Readthrough activity was measured by flow cytometry and expressed as the percentage of viable cells expressing both tdTomato and EGFP above baseline ("bi-+ cells %"). (Figure 19) In Neuro-2a cells co-transfected with an expression construct containing the EGFP-Q69X-TAA reporter (SEQ ID NO: 175), the Gln expression is shown. TTA This graph shows the readthrough activity of suppressor tRNAs (SEQ ID NO: 36-48). "Mock" indicates mock-transfected cells, "EGFP" indicates cells transfected with a PTC-less version of the EGFP reporter, "EV" (empty vector) indicates cells transfected with an expression construct containing neither tRNA nor the EGFP reporter, and "TTG" indicates cells co-transfected with an expression construct containing the EGFP-Q69X-TAA reporter and wild-type Gln-tRNA with the TTG anticodon. Readthrough activity is measured by flow cytometry and expressed as the percentage of viable cells expressing GFP above the background. Error bars represent the standard deviation of the data. (Figure 20) In Neuro-2a cells co-transfected with an expression construct containing the EGFP-Q69X-TAG reporter (SEQ ID NO: 176), the Gln expression is shown. CTA This graph shows the readthrough activity of suppressor tRNAs (SEQ ID NO: 78-90). "Mock" indicates mock-transfected cells, "EGFP" indicates cells transfected with a PTC-less version of the EGFP reporter, "EV" (empty vector) indicates cells transfected with an expression construct containing neither tRNA nor the EGFP reporter, and "TTG" indicates cells co-transfected with an expression construct containing the EGFP-Q69X-TAG reporter and wild-type Gln-tRNA with the TTG anticodon. Readthrough activity is measured by flow cytometry and expressed as the percentage of viable cells expressing GFP above the background. Error bars represent the standard deviation of the data. (Figure 21) Neuro-2a cells approximately 24 hours after transfection with an expression construct containing the EGFP-R96X-TGA reporter ("GFP-PTC"), wherein (i) on the same construct, the indicated copy number of Arg TCA The images show fluorescence images of Neuro-2a cells that were either (ii) treated with suppressor tRNA #115 (SEQ ID NO: 18), (iii) treated with the indicated concentration of atalurene, or (iv) treated with the indicated concentration of G418. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and at this point, the indicated concentrations of the indicated drugs were added. The controls in the left column are expression constructs containing wild-type EGFP ("WT-GFP") and the indicated drugs or the indicated copy number of Arg TCA The suppressor tRNA was transfected. (Figure 22) This graph shows the percentage of GFP-positive cells measured by flow cytometry approximately 48 hours after transfection. For Neuro-2a cells, an expression construct containing the EGFP-R96X-TGA reporter ("GFP-PTC") was transfected, and (i) on the same construct, the indicated number of Arg TCA The cells were either (ii) treated with the indicated concentration of atalurene, (iii) treated with the indicated concentration of gentamicin, or (iv) treated with the indicated concentration of G418, or (ii) treated with the indicated concentration of G418. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and at this point, the indicated concentrations of the indicated drugs were added. A reporter containing wild-type EGFP without PTCs ("WT-GFP") was used as a control. "Mock" indicates mock-transfected cells. "4XTCG" indicates cells transfected with an expression construct containing four copies of wild-type Arg-tRNA with TCG anticodons and the EGFP-R96X-TGA reporter. The plots show the percentage of viable cells expressing EGFP above the background. The percentage of cells expressing GFP was 0.7–1.6% in negative controls, 0.9–4.9% in atallen-treated cells, 1.2–6.5% in gentamicin-treated cells, and 6.7–26.7% in G418-treated cells, compared to Arg TCA The suppressor expression levels ranged from 73.0% to 76.2% in cells expressing the suppressor. (Figure 23) This graph shows the cell viability from Figure 22, measured by flow cytometry approximately 48 hours after transfection. For Neuro-2a cells, an expression construct containing the EGFP-R96X-TGA reporter ("GFP-PTC") was transfected, and (i) on the same construct, the indicated number of Arg cells were transfected. TCACells were transfected with an expression construct containing suppressor tRNA #115 (SEQ ID NO: 18), (ii) treated with the indicated concentration of atalurene, (iii) treated with the indicated concentration of gentamicin, or (iv) treated with the indicated concentration of G418. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and the indicated concentrations of the indicated drugs were added at this point. A reporter containing wild-type GFP without PTCs ("WT-GFP") was used as a control. "Mock" indicates mock-transfected cells. "4XTCG" indicates cells transfected with an expression construct containing four copies of wild-type Arg-tRNA with TCG anticodons and the EGFP-R96X-TGA reporter. Cell viability was evaluated by flow cytometry using 7-aminoactinomycin D (7-AAD), a membrane-impermeable dye normally excluded from viable cells. (Figure 24) Three clinically relevant Gln(Q)-to-TAG PTC mutations within SCN1A associated with Dravet syndrome (W1397 * S1505 * , and Q1810 * In Flp-In-293 cells transiently co-transfected with the indicated bifluorescent reporter construct containing the linker region (SEQ ID NO: 889, 891, and 893) derived from ), the indicated Gln CTAThis graph shows the readthrough activity of suppressor tRNAs (SEQ ID NO: 178-190). "Mock" indicates mock-transfected cells, "No PTC" indicates cells transfected with PTC-less versions of the bifluorescent reporter construct (SEQ ID NO: 890, 892, and 894), "EV" (empty vector) indicates cells transfected with an expression construct containing neither tRNA nor fluorescent reporter, and "TTG" indicates cells co-transfected with the shown bifluorescent reporter construct and an expression construct containing wild-type Gln-tRNA with a TTG anticodon. Readthrough activity was measured by flow cytometry approximately 24 hours after transfection and is expressed as the percentage of viable cells expressing both tdTomato and EGFP above baseline ("Bifluorescent + cells %"). (Figure 25) Clinically relevant PTC mutations within SCN1A associated with Dravet syndrome (W1397 * In the Flp-In-293 cell line incorporating a bifluorescent reporter construct containing a linker region (SEQ ID NO:889) derived from ), the Gln CTA This graph shows the readthrough activity of suppressor tRNAs (SEQ ID NO: 178-190). "Mock" represents mock-transfected cells, "RFP-EGFP" represents the Flp-In-293 cell line incorporating a PTC-less version of the bifluorescence reporter construct (SEQ ID NO: 890), "EV" (empty vector) represents cells transfected with an expression construct containing neither tRNA nor the EGFP reporter, and "TTG" represents cells transfected with wild-type Gln-tRNA containing the TTG anticodon. Readthrough activity was measured by flow cytometry approximately 24 hours after transfection and is expressed as the percentage of cells expressing both tdTomato and EGFP beyond the background ("bivalent + cells %"). (Figure 26A) (i) 200 bp upstream neighboring genomic DNA from tRNA-Arg-TCG-1-1 (SEQ ID NO: 26) and 104 bp downstream neighboring genomic DNA from tRNA-Arg-TCG-1-1 (SEQ ID NO: 32) ("Neighboring 300"), (ii) 20 bp upstream neighboring genomic DNA from tRNA-Arg-TCG-1-1 (SEQ ID NO: 895) and 17 bp downstream neighboring genomic DNA from tRNA-Arg-TCG-1-1 (SEQ ID NO: 896) ("Neighboring 20"), (iii) 10 bp upstream neighboring genomic DNA from tRNA-Arg-TCG-1-1 (SEQ ID NO: 897) and 17 bp downstream neighboring genomic DNA from tRNA-Arg-TCG-1-1 (SEQ ID NO: Under the context of either (iv) 0 bp upstream neighboring genomic DNA from tRNA-Arg-TCG-1-1 and 17 bp downstream neighboring genomic DNA from tRNA-Arg-TCG-1-1 (SEQ ID NO: 896) ("neighboring 0"), the EGFP-R96X-TGA reporter (SEQ ID NO: 31) and a single copy of Arg TCA The fluorescence measured by flow cytometry in Neuro-2a cells transfected with an expression construct containing suppressor tRNA #115 (SEQ ID NO: 18) is shown. Details of the expression vector are shown in Table 11. "GFP-PTC" indicates cells transfected with the EGFP-R96X-TGA reporter alone (SEQ ID NO: 31), and "GFP" indicates cells transfected with a version of the EGFP reporter lacking PTC. Readthrough activity was measured by flow cytometry approximately 24 hours after transfection. The data are presented as a histogram showing the frequency distribution of the data against fluorescence intensity in cells expressing EGFP above the background. (Figure 26B) Figure 26B shows the percentage of EGFP-positive cells among all viable cells ("GFP+%") and the mean EGFP intensity in viable cells expressing EGFP above the background level ("mean GFP signal") for the cells shown in Figure 26A. (Figure 27) This is a schematic diagram of the construct used to test the effect of a 5' leader sequence on the read-through of immature stop codons (PTCs) by suppressor tRNA. The construct consists of (i) a 100 bp 5' leader sequence derived from genomic DNA located upstream of a highly expressed tRNA gene in HEK293 cells, and (ii) a single copy of Arg TCA Suppressor tRNA #115 (SEQ ID NO: 18) or Gln TTA It contains either suppressor tRNA#163 (SEQ ID NO:45) and (iii) an RNA polymerase III termination signal ("termination"). (Figure 28) Arg, as shown, measured by flow cytometry in Flp-In-293 cells approximately 24 hours after transfection. TCA This graph shows the read-through activity of suppressor tRNA expression constructs. Under the context of the 100bp upstream genomic DNA reader sequences (SEQ ID NO: 869~888) shown, (i) EGFP-R96X-TGA reporter (SEQ ID NO: 31) and (ii) Arg TCA Cells were co-transfected with a construct containing suppressor tRNA#115 (SEQ ID NO:18). "WT-EGFP" indicates cells transfected with a reporter containing wild-type GFP without PTCs, "EV" (empty vector) indicates cells co-transfected with an expression construct containing neither tRNA nor the EGFP reporter, and "26 / 27" indicates cells co-transfected with ArgTCA suppressor tRNA#115 (SEQ ID NO:18) under the context of 200 bp upstream neighboring genomic DNA (SEQ ID NO:26) and 200 bp downstream neighboring genomic DNA (SEQ ID NO:27) derived from tRNA-Arg-TCG-1-1. The plot shows the percentage of viable cells expressing EGFP above the background. The percentage of cells expressing EGFP was 0.4% in the empty vector control compared to Arg. TCA The suppressor expression levels ranged from 17.2% to 33.7% in cells expressing the suppressor. (Figure 29) Arg, as shown, measured by flow cytometry in Flp-In-293 cells approximately 24 hours after transfection. TCA This graph shows the read-through activity of suppressor tRNA expression constructs. Under the context of the 100bp upstream genomic DNA reader sequences (SEQ ID NO: 869~888) shown, (i) EGFP-R96X-TGA reporter (SEQ ID NO: 31) and (ii) Arg TCA Cells were co-transfected with a construct containing suppressor tRNA#115 (SEQ ID NO:18). "WT-EGFP" indicates cells transfected with a reporter containing wild-type GFP without PTCs, "EV" (empty vector) indicates cells co-transfected with an expression construct containing neither tRNA nor the EGFP reporter, and "26 / 27" indicates cells co-transfected with ArgTCA suppressor tRNA#115 (SEQ ID NO:18) under the context of 200 bp upstream neighboring genomic DNA (SEQ ID NO:26) and 200 bp downstream neighboring genomic DNA (SEQ ID NO:27) derived from tRNA-Arg-TCG-1-1. The plot shows the mean EGFP intensity in cells expressing EGFP above the background. The mean EGFP intensity is 602 in the empty vector control compared to Arg. TCA In cells expressing the suppressor, the range was 1990–4319. (Figure 30) Gln, as measured by flow cytometry in Flp-In-293 cells approximately 24 hours after transfection. TTA This graph shows the read-through activity of suppressor tRNA expression constructs. Under the context of the 100bp upstream genomic DNA reader sequences (SEQ ID NO: 869~888) shown, (i) EGFP-Q69X-TAA reporter (SEQ ID NO: 175) and (ii) Gln TTACells were co-transfected with a construct containing suppressor tRNA #163 (SEQ ID NO: 45). "WT-EGFP" indicates cells transfected with a reporter containing wild-type GFP without PTCs, "EV" (empty vector) indicates cells co-transfected with an expression construct that does not contain either tRNA or the EGFP reporter, and "173 / 174" indicates the sequence of 200 bp upstream neighboring genomic DNA (SEQ ID NO: 173) from tRNA-Gln-TTG-1-1 and 200 bp downstream neighboring genomic DNA (SEQ ID NO: 174) from tRNA-Gln-TTG-1-1. TTA This shows cells co-transfected with suppressor tRNA #163 (SEQ ID NO: 45). The plot shows the percentage of viable cells expressing EGFP above the background level. The percentage of cells expressing EGFP is 0.3% in the blank vector control compared to Gln. TTA The suppressor expression levels ranged from 21.4% to 35.7% in cells expressing the suppressor. (Figure 31) Gln, as shown, was measured by flow cytometry in Flp-In-293 cells approximately 24 hours after transfection. TTA This graph shows the read-through activity of suppressor tRNA expression constructs. Under the context of the 100bp upstream genomic DNA reader sequences (SEQ ID NO: 869~888) shown, (i) EGFP-Q69X-TAA reporter (SEQ ID NO: 175) and (ii) Gln TTA Cells were co-transfected with a construct containing suppressor tRNA #163 (SEQ ID NO: 45). "WT-EGFP" indicates cells transfected with a reporter containing wild-type GFP without PTCs, "EV" (empty vector) indicates cells co-transfected with an expression construct that does not contain either tRNA or the EGFP reporter, and "173 / 174" indicates the sequence of 200 bp upstream neighboring genomic DNA (SEQ ID NO: 173) from tRNA-Gln-TTG-1-1 and 200 bp downstream neighboring genomic DNA (SEQ ID NO: 174) from tRNA-Gln-TTG-1-1.TTA This shows cells co-transfected with suppressor tRNA #163 (SEQ ID NO: 45). The plot shows the mean EGFP intensity in cells expressing EGFP above the background level. The mean EGFP intensity is 387 in the blank vector control compared to Gln. TTA In cells expressing the suppressor, the range was 1702–3822. (Figure 32) This table summarizes the results from Figures 28-31, and the values are normalized for cells transfected with wild-type GFP that do not have PTC. (Figure 33) This graph shows the percentage of EGFP-positive cells measured by flow cytometry in three independent experiments approximately 48 hours after transfection. For Neuro-2a cells, an expression construct containing the EGFP-Q69X-TAA reporter ("EGFP-PTC") (SEQ ID NO: 175) was transfected, and (i) the same construct was transfected with the indicated number of Gln TTACells were either (ii) treated with the indicated concentration of atalurene, (iii) treated with the indicated concentration of gentamicin, or (iv) treated with the indicated concentration of G418. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and at this point, the indicated concentrations of the indicated drugs were added. A reporter containing wild-type EGFP without PTCs ("EGFP") was used as a control. "Mock" indicates mock-transfected cells, "No tRNA" indicates cells transfected with the indicated EGFP expression construct alone, and "4X-Gln-TTG" indicates cells transfected with an expression construct containing four copies of wild-type Gln-tRNA with TTG anticodons and the EGFP-Q69X-TAA reporter. The plots show the percentage of viable cells expressing GFP above the background. Error bars represent the standard deviation of the data. The percentage of cells expressing GFP was 0.2–0.7% in negative controls, 0.4–0.6% in atallen-treated cells, 0.4% in gentamicin-treated cells, and 1.7–4.5% in G418-treated cells. TTA The suppressor expression rate ranged from 64.7% to 67.3% in cells expressing the suppressor. (Figure 34) This graph shows the cell viability from Figure 33, measured by flow cytometry approximately 48 hours after transfection. For Neuro-2a cells, an expression construct containing the EGFP-Q69X-TAA reporter ("EGFP-PTC") (SEQ ID NO: 175) was transfected, and (i) the same construct was transfected with the indicated number of Gln TTACells were either (ii) treated with the indicated concentration of atalurene, (iii) treated with the indicated concentration of gentamicin, or (iv) treated with the indicated concentration of G418. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and at this point, the indicated concentrations of the indicated drugs were added. A reporter containing wild-type EGFP without PTCs ("EGFP") was used as a control. "Mock" indicates mock-transfected cells, "No tRNA" indicates cells transfected with the indicated EGFP expression construct alone, and "4X-Gln-TTG" indicates cells transfected with an expression construct containing four copies of wild-type Gln-tRNA with TTG anticodons and the EGFP-Q69X-TAA reporter. Cell viability was evaluated by flow cytometry using 7-aminoactinomycin D (7-AAD), a membrane-impermeable dye that is normally eliminated from viable cells. (Figure 35) This graph shows the percentage of EGFP-positive cells measured by flow cytometry in three independent experiments approximately 48 hours after transfection. For Neuro-2a cells, an expression construct containing the EGFP-Q69X-TAG reporter ("EGFP-PTC") (SEQ ID NO: 176) was transfected, and (i) the same construct was transfected with the indicated number of Gln CTACells were either (ii) treated with the indicated concentration of atalene, (iii) treated with the indicated concentration of gentamicin, or (iv) treated with the indicated concentration of G418, or (iv) treated with the indicated concentration of G418. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and at this point, the indicated concentrations of the indicated drugs were added. A reporter containing wild-type EGFP without PTCs ("EGFP") was used as a control. "Mock" indicates mock-transfected cells, "No tRNA" indicates cells transfected with the indicated EGFP expression construct alone, and "4X-Gln-TTG" indicates cells transfected with an expression construct containing four copies of wild-type Gln-tRNA with TTG anticodons and the EGFP-Q69X-TAA reporter. The plots show the percentage of viable cells expressing GFP above the background. The percentage of cells expressing GFP was 0.5–0.8% in negative controls, 0.5–0.7% in atallen-treated cells, 0.5–1.1% in gentamicin-treated cells, and 13.6–20.6% in G418-treated cells. CTA The suppressor expression rate ranged from 73.1% to 78.2% in cells expressing the suppressor. (Figure 36) This graph shows the cell viability from Figure 35, measured by flow cytometry approximately 48 hours after transfection. For Neuro-2a cells, an expression construct containing the EGFP-Q69X-TAG reporter ("EGFP-PTC") (SEQ ID NO: 176) was transfected, and (i) on the same construct, the indicated copy number of Gln CTACells were either (ii) treated with the indicated concentration of atalurene, (iii) treated with the indicated concentration of gentamicin, or (iv) treated with the indicated concentration of G418. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and at this point, the indicated concentrations of the indicated drugs were added. A reporter containing wild-type EGFP without PTCs ("EGFP") was used as a control. "Mock" refers to mock-transfected cells, "No tRNA" refers to cells transfected with the indicated EGFP expression construct alone, and "4X-Gln-TTG" refers to cells transfected with an expression construct containing four copies of wild-type Gln-tRNA with TTG anticodons and the EGFP-Q69X-TAA reporter. Cell viability was evaluated by flow cytometry using 7-aminoactinomycin D (7-AAD), a membrane-impermeable dye that is normally eliminated from viable cells. (Figure 37A) Western blot showing the rescue of full-length SCN1A protein expression by suppressor tRNA. For Flp-In-293 cells, Arg(R)-to-TGA PTC(R1407X) and a 3xFLAG tag peptide at the C-terminus were used. Mouse SCN1A (SEQ ID NO:899) containing TIFF2022554357000001.tif4128 ("SCN1a (R1407 * Transfect an expression construct containing (i)Arg TCACells were co-transfected with an expression construct containing suppressor tRNA #115 (SEQ ID NO: 18) ("Arg>TGA#115"), or (ii) treated with atalurene at the indicated concentration, (iii) treated with gentamicin at the indicated concentration, or (iv) treated with G418 at the indicated concentration. "SCN1a (wt)" indicates cells transfected with an expression construct containing wild-type mouse SCN1A and a C-terminal 3xFLAG tag peptide (SEQ ID NO: 898). Proteins were isolated 24 hours after transfection, and SCN1A was detected using a monoclonal anti-FLAG M2 antibody. Molecular weights based on protein molecular weight markers are shown on the left side of the gel. (Figure 37B) This is the quantification of the Western blot shown in Figure 37A. The intensity of the band corresponding to the size of the full-length SCN1A protein was measured using ImageJ, and all intensity values were normalized to the wild-type SCN1A protein ("SCN1a (wt)" lane). Expression vectors containing mutant SCN1A and Arg TCA Cells co-transfected with an expression vector containing suppressor tRNA expressed more than 70% of the full-length SCN1A expressed by cells transfected with an expression construct containing wild-type SCN1A. (Figure 38A) Western blot showing rescue of full-length SCN1A protein expression by suppressor tRNA. (i) Arginine-to-TGA PTC (R1407X) and a 3x FLAG tag peptide at the C-terminus. Mouse SCN1A (SEQ ID NO:899) containing TIFF2022554357000002.tif4128 ("SCN1a (R1407 * (ii)#104 Arg TCA Suppressor tRNA (SEQ ID NO:6) ("Sup#104"), #106 Arg TCA Suppressor tRNA (SEQ ID NO:8) ("Sup#106"), or Arg TCAFlp-In-293 cells were co-transfected with either suppressor tRNA #115 (SEQ ID NO: 18) ("Sup#115"). "SCN1a (wt)" indicates cells transfected with an expression construct containing wild-type mouse SCN1A and a C-terminal 3xFLAG tag peptide (SEQ ID NO: 898). Proteins were isolated 24 hours after transfection, and SCN1A was detected using a monoclonal anti-FLAG M2 antibody. Molecular weights based on protein molecular weight markers are shown on the left side of the gel. (Figure 38B) This is the quantification of the Western blot shown in Figure 38A. The intensity of the band corresponding to the size of the full-length SCN1A protein was measured using ImageJ, and all intensity values were normalized to the wild-type SCN1A protein ("SCN1a (wt)" lane). Expression vectors containing mutant SCN1A and Arg TCA Cells co-transfected with an expression vector containing suppressor tRNA expressed more than 30% (Sup#104), more than 60% (Sup#106), or more than 70% (Sup#115) of the full-length SCN1A expressed by cells transfected with an expression construct containing wild-type SCN1A. (Figure 39A) Western blot showing rescue of full-length SCN1A protein expression by suppressor tRNA. Flp-In-293 cells were cultured in a 6-well cell culture plate and (i) arginine-to-TGA PTC (R1407X) with a 3xFLAG tag peptide at the C-terminus. Mouse SCN1A (SEQ ID NO:899) containing TIFF2022554357000003.tif4128 ("SCN1a (R1407 * (ii) an expression construct containing )") and Arg at the indicated concentration TCA The cells were co-transfected with suppressor tRNA #115 (SEQ ID NO: 18) ("Arg>TGA#115"). 1x was administered with 400 ng of Arg per well. TCA The suppressor tRNA construct is shown, with 0.3x being 133 ng of Arg per well. TCAThe suppressor tRNA construct is shown, with 0.1x being 40 ng of Arg per well. TCA The suppressor tRNA construct is shown, with 0.03x being 13 ng of Arg per well. TCA The suppressor tRNA construct is shown. "SCN1a (wt)" indicates cells transfected with an expression construct containing wild-type mouse SCN1A and a C-terminal 3xFLAG tag peptide (SEQ ID NO: 898). Proteins were isolated 24 hours after transfection, and SCN1A was detected using a monoclonal anti-FLAG M2 antibody. Molecular weights based on protein molecular weight markers are shown on the left side of the gel. (Figure 39B) This is the quantitative analysis of the Western blot shown in Figure 39A. The intensity of the band corresponding to the size of the full-length SCN1A protein was measured using ImageJ, and all intensity values were normalized to the wild-type SCN1A protein ("SCN1a (wt)" lane). (Figure 40) This is a schematic diagram of the constructs packaged in the AAV-PHP.eB capsid. Construct 262 contains wild-type EGFP promoted by the EF1a promoter. Construct 269 contains EGFP-R96X-TGA (SEQ ID NO: 177) and two copies of Arg, promoted by the EF1a promoter under the context of a 55 bp upstream adjacent genomic DNA (SEQ ID NO: 900) derived from tRNA-Tyr-GTA-5-1. TCA It contains suppressor tRNA #115 (SEQ ID NO: 18) ("TCA-115"). Both constructs contain 5' and 3' ITR sequences derived from AAV2 that provide cis-active elements for AAV replication and packaging. (Figure 41) shows the read-through activity of the suppressor tRNA delivered by AAV. AAV-PHP.eB containing the constructs shown in Figure 40 was prepared by Vigene Biosciences. 293 cells were pre-transfected with an expression construct containing the LY6A gene, which is necessary for reliable transduction by AAV-PHP.eB, 48 hours prior to AAV transduction. Cells were transfected at an MOI of 1E5 vg / cell. Where shown, cells were also transfected with an expression construct containing the EGFP-R96X-TGA reporter (SEQ ID NO:31) and an expression construct containing the ArgTCA suppressor tRNA #115 (SEQ ID NO:18). EGFP signaling was quantified by immunofluorescence 72 hours after transduction. Live cell images were acquired using the EVOS FL Auto 2 imaging system. CellProfiler software was used to isolate and extract the EGFP intensity incorporated into the nucleus in each image. These values were averaged across all nuclei under each condition. All values were normalized by subtracting the background mean, which is the incorporation of EGFP intensity under the negative control condition, from each of these means. The plots show the normalized GFP intensity %, with all values normalized for cells transduced with AAV-PHP.eB containing construct 262. (Figure 42) Fluorescence measured by flow cytometry in Neuro-2a cells used in ribosome footprint profiling analysis is shown. (i) EGFP-R96X-TGA reporter (SEQ ID NO: 177) and Arg on the same construct. TCA Expression construct containing suppressor tRNA #001 (SEQ ID NO:11) ("Arg TCA Cells were transfected with either (ii) an expression construct containing an EGFP reporter without PTC ("WT-EGFP") or (ii) a version of the EGFP reporter lacking PTC ("WT-EGFP"). (Figure 43) This shows the magnification of change in the 3' UTR read density distribution (determined by ribosome profiling) between two Neuro-2a cell populations shown in Figure 42. (i) EGFP-R96X-TGA reporter (SEQ ID NO: 177) and Arg on the same construct. TCA An expression construct containing suppressor tRNA #001 (SEQ ID NO:11) ("Arg TCA Cells were transfected with either (ii) an expression construct containing an EGFP reporter lacking PTC ("WT-EGFP"). Approximately 48 hours after transfection, cells were lysed and subjected to ribosome footprint profiling. Non-coding RNA was removed by excising the adapter from the live reads using Trimmomatic and then aligning them to the Ensembl mouse mm10 ncRNA reference using bowtie2. The remaining reads were again aligned to the UCSC mm10 mouse reference assembly using bowtie2. Multiple-mapped reads were discarded. The final set of aligned reads obtained was quantified using the RiboProfiling package in R and a custom Python script. Using Python, plots were created to test the 3' UTR occupancy and change ratio in each gene with 20 or more uniquely mapped reads, and the distribution in genes with each native stop codon was compared using the two-sample Kolmogorov-Smirnov test. [Modes for carrying out the invention]
[0030] Detailed explanation This invention is based in part on the discovery of tRNAs (e.g., suppressor tRNAs) that enable the insertion of amino acids into gene products encoded by genes in mammalian cells at locations where, otherwise, a truncated gene product would result due to immature stop codons (PTCs) within those genes. This invention is further based on the discovery that tRNAs that enable the insertion of amino acids into gene products encoded by genes at locations where, otherwise, a truncated gene product would result due to PTCs within those genes, can be used to treat diseases mediated by PTCs within genes in subjects.
[0031] Therefore, in one aspect, the present invention provides tRNA (e.g., isolated tRNA) containing the nucleotide sequence shown in Table 2.
[0032] In another aspect, the present invention provides an expression vector comprising a nucleotide sequence encoding tRNA, for example, as shown in Tables 1-3. In a particular embodiment, the expression vector comprises a nucleotide sequence encoding tRNA in 1, 2, 3, 4, or more than 4 copies. In a particular embodiment, the expression vector comprises a nucleotide sequence corresponding to a genomic DNA sequence adjacent to the wild-type tRNA gene. For example, in a particular embodiment, the expression vector comprises the nucleotide sequence shown in Table 4.
[0033] In another aspect, the present invention provides a pharmaceutical composition comprising any of the above-mentioned tRNAs or any of the above-mentioned expression vectors and a pharmaceutically acceptable excipient.
[0034] In another aspect, the present invention provides a method for expressing a functional gene product encoded by a gene containing an immature stop codon in mammalian cells, the method comprising the steps of introducing into cells an expression vector containing an effective amount of tRNA (for example, including SEQ ID NO: 6-9, 11, 16-22, 35-40, 44, 45, 178-182, 186, or 187, as shown in Tables 1-3 below), thereby enabling the incorporation of amino acids into the gene product at a position in the gene product where a truncated gene product would otherwise result due to an immature stop codon.
[0035] In any particular aspect of the above method, the cells contain fewer truncated gene products than cells without tRNA. For example, in a particular aspect, the cells contain less than approximately 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of truncated gene products compared to cells without tRNA. In certain embodiments, cells contain approximately 5% to 80%, 5% to 60%, 5% to 40%, 5% to 20%, 5% to 10%, 10% to 80%, 10% to 60%, 10% to 40%, 10% to 20%, 20% to 80%, 20% to 60%, 20% to 40%, 40% to 80%, 40% to 60%, or 60% to 80% of truncated gene products compared to cells lacking tRNA. In certain embodiments, no detectable truncated gene products are present in the cells. The amount or expression of truncated gene products can be measured by any method known in the art, such as Western blotting or ELISA.
[0036] In certain embodiments, cells contain a greater amount of functional gene products than cells without tRNA. For example, in certain embodiments, this method increases the amount of functional gene products in cells, tissues, or subjects by approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 350%, 400%, 450%, or 500% compared to cells, tissues, or subjects without tRNA. In certain aspects, this method can reduce the amount of functional gene products in cells, tissues, or subjects by approximately 20% to 200%, 20% to 180%, 20% to 160%, 20% to 140%, 20% to 120%, 20% to 100%, 20% to 80%, and 2% compared to cells, tissues, or subjects without tRNA. 0% to approximately 60%, approximately 20% to approximately 40%, approximately 40% to approximately 200%, approximately 40% to approximately 180%, approximately 40% to approximately 160%, approximately 40% to approximately 140%, approximately 40% to approximately 120%, approximately 40% to approximately 100%, approximately 40% to approximately 80%, approximately 40% to approximately 60%, approximately 60% to approximately 200%, approximately 60% to approximately 180%, approximately 60% to approximately 160%, approximately 60% to approximately 14 0%, approximately 60% to approximately 120%, approximately 60% to approximately 100%, approximately 60% to approximately 80%, approximately 80% to approximately 200%, approximately 80% to approximately 180%, approximately 80% to approximately 160%, approximately 80% to approximately 140%, approximately 80% to approximately 120%, approximately 80% to approximately 100%, approximately 100% to approximately 200%, approximately 100% to approximately 180%, approximately 100% to approximately 160%, approximately 100% to approximately Increase by 140%, approximately 100% to approximately 120%, approximately 120% to approximately 200%, approximately 120% to approximately 180%, approximately 120% to approximately 160%, approximately 120% to approximately 140%, approximately 140% to approximately 200%, approximately 140% to approximately 180%, approximately 140% to approximately 160%, approximately 160% to approximately 200%, approximately 160% to approximately 180%, or approximately 180% to approximately 200%. The amount or expression of the functional gene product can be measured by any method known in the art, for example, by Western blotting or ELISA.
[0037] In certain embodiments, tRNA allows amino acids to be incorporated into the position corresponding to an immature stop codon in the gene product (i.e., tRNA enables read-through of an immature stop codon), but does not allow substantial amounts of amino acids to be incorporated into the position corresponding to a native stop codon in the gene product (i.e., tRNA does not enable read-through of a native stop codon). For example, in certain embodiments, the disclosed tRNA does not increase the read-through of a native stop codon (or all native stop codons) in a cell, tissue, or subject, or increases the read-through by about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 20%, about 30%, about 40%, or less than about 50% compared to cells, tissues, or subjects not in contact with the tRNA. The read-through of a native stop codon can be measured by any method known in the art, for example, by ribosome profiling as described in Example 13 herein.
[0038] In any particular embodiment of the above method, the gene is selected from the genes shown in Table 5 or Table 6. In any particular embodiment, the gene is the SCN1A gene.
[0039] In another aspect, the present invention provides a method for expressing a functional SCN1A gene product encoded by an SCN1A gene containing an immature stop codon in cells, the method comprising the steps of introducing into cells an expression vector containing an effective amount of tRNA (for example, including SEQ ID NO: 6-9, 11, 16-22, 35-40, 44, 45, 178-182, 186, or 187, as shown in Tables 1-3 below), thereby enabling the incorporation of amino acids into the SCN1A gene product at a position in the SCN1A gene product where a shortened SCN1A gene product would otherwise result due to an immature stop codon.
[0040] In another aspect, the present invention provides a method for increasing the activity of a voltage-opening sodium channel encoded by the SCN1A gene containing an immature stop codon in a cell, the method comprising introducing into a cell an expression vector containing an effective amount of tRNA (for example, including SEQ ID NO: 6-9, 11, 16-22, 35-40, 44, 45, 178-182, 186, or 187, as shown in Tables 1-3 below), thereby enabling the incorporation of an amino acid into the SCN1A gene product at a position in the SCN1A gene product where a truncated SCN1A gene product would otherwise result due to an immature stop codon.
[0041] In another aspect, the present invention provides a method for treating an immature stop codon-mediated disorder in a subject that needs to treat such disorder, the subject having a gene having an immature stop codon, the method comprising the steps of administering to the subject an effective amount of an expression vector containing tRNA or a nucleotide sequence encoding said tRNA (for example, including SEQ ID NO: 6-9, 11, 16-22, 35-40, 44, 45, 178-182, 186, or 187, as shown in Tables 1-3 below), thereby treating the disorder in the subject. In a particular embodiment, the disorder is selected from the disorders shown in Table 5 or Table 6.
[0042] In another aspect, the present invention provides a method for treating Dravet syndrome in subjects in need, wherein the subjects have an SCN1A gene with an immature stop codon, and the method comprises the steps of administering to the subject an effective amount of an expression vector containing tRNA or a nucleotide sequence encoding said tRNA (for example, as shown in Tables 1-3 below, including, for example, SEQ ID NO: 6-9, 11, 16-22, 35-40, 44, 45, 178-182, 186, or 187), thereby treating Dravet syndrome in the subject.
[0043] I. tRNA and suppressor tRNA During protein synthesis, transfer RNA (tRNA) delivers amino acids to ribosomes for incorporation into the elongating protein (polypeptide) chain. tRNA is typically about 70–100 nucleotides long, and active tRNA contains a 3' CCA sequence, which can be transcribed into the tRNA during its synthesis or added during subsequent post-transcriptional processing. During aminoacylation, the amino acid added to the tRNA molecule is covalently attached to the 2' or 3' hydroxyl group of the 3'-terminal ribose, forming aminoacyl-tRNA (aa-tRNA). While amino acids can spontaneously move from the 2'-hydroxyl group to the 3'-hydroxyl group or vice versa, it is understood that they are incorporated into the elongating protein chain on the ribosome from the 3'-OH position. The loop at the other end of the folded aa-tRNA molecule contains a 3-base sequence known as the anticodon. When this anticodon sequence hybridizes or forms a base pair with a complementary 3-base codon sequence in messenger RNA (mRNA) bound to a ribosome, the aa-tRNA binds to the ribosome, and its amino acid is incorporated into the polypeptide chain synthesized by that ribosome. Since all tRNAs that form a base pair with a particular codon are aminoacylated with a single specific amino acid, the tRNA is used to translate the gene code. Each of the 61 non-stop codons in mRNA guides the binding of its homologous aa-tRNA and the addition of a single specific amino acid to the elongating polypeptide chain synthesized by the ribosome.
[0044] tRNAs are generally highly conserved and often function across species. Therefore, tRNAs derived from bacterial tRNAs, non-mammalian eukaryotic tRNAs, or mammalian (e.g., human) tRNAs may be useful in carrying out the present invention. Nucleotide sequences encoding naturally occurring human tRNAs are publicly known and generally available to those skilled in the art through sources such as Genbank. See also Sprinzl et al. (2005) NUCLEIC ACIDS RES. 33: D139-40; Buckland et al. (1996) GENOMICS 35(1):164-71; Schimmel et al. (Eds.) (1979) “Transfer-RNA: Structure, Properties, and Recognition,” Cold Spring Harbor Laboratory; Agris (1983) “The Modified Nucleosides of Transfer RNA, II,” Alan R. Liss Inc. tRNAs are generally highly conserved and often function across species.
[0045] Suppressor tRNAs are modified tRNAs that insert the appropriate amino acid into a mutation site, such as a PTC, within a protein-coding gene. The use of the term "suppressor" is based on the fact that, under certain circumstances, this modified tRNA "suppresses" the phenotypic effect of the coding mutation. Suppressor tRNAs typically involve mutations (modifications) either within the anticodon to alter codon specificity, or at several positions that alter the aminoacylation properties of the tRNA.
[0046] In certain embodiments, a tRNA (e.g., suppressor tRNA) contains a modified anticodon region, and the modified anticodon hybridizes to a codon different from the corresponding naturally occurring anticodon. In certain embodiments, the modified anticodon hybridizes to a stop codon, e.g., a PTC, and as a result, the tRNA incorporates an amino acid into the gene product rather than terminating protein synthesis. In certain embodiments, the modified anticodon hybridizes to an immature stop codon, and as a result, the tRNA incorporates an amino acid into the gene product at a position where a shortened gene product would otherwise result from the immature stop codon.
[0047] In certain embodiments, the tRNA includes an anticodon that hybridizes to a codon selected from UAG (i.e., the "amber" stop codon), UGA (i.e., the "opal" stop codon), and UAA (i.e., the "ochre" stop codon). In certain embodiments, the anticodon hybridizes to a codon selected from UGA~UAA. In certain embodiments, the anticodon hybridizes to UGA. In certain embodiments, the tRNA includes an anticodon that hybridizes to a non-standard stop codon, e.g., a 4-nucleotide codon (see, e.g., Moore et al. (2000) J. MOL. BIOL. 298:195 and Hohsaka et al. (1999) J. AM. CHEM. SOC. 121:12194).
[0048] In certain embodiments, tRNA can be aminoacylated with any native amino acid. For example, tRNA may be aminoacylated with alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. In certain embodiments, tRNA can be aminoacylated with serine, leucine, glutamine, or arginine. In certain embodiments, tRNA can be aminoacylated with glutamine or arginine. In certain embodiments, tRNA can be aminoacylated with arginine.
[0049] In certain embodiments, the tRNA may (i) contain an anticodon that hybridizes to a codon shown in Table 1, and (ii) be aminoacylated or aminoacylated with an amino acid shown in Table 1.
[0050] [Table 1] TIFF2022554357000005.tif122137
[0051] In a particular embodiment, the tRNA comprises, essentially consists of, or comprises nucleotide sequences, including, the nucleotide sequences shown in Table 2. In a particular embodiment, the tRNA comprises, essentially consists of, or comprises nucleotide sequences, having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with respect to the nucleotide sequences shown in Table 2. In a particular embodiment, the tRNA is essentially composed of or consists of a nucleotide sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a nucleotide sequence selected from SEQ ID NO: 19-21, 37, 39, 40, 44, 179, 181, 182, and 186. Through the detailed explanation, in each example in which a tRNA contains, is essentially derived from, or consists of a nucleotide sequence containing one or more thymine (T) molecules, it is also assumed that the tRNA may contain, be essentially derived from, or consist of the same nucleotide sequence containing uracil (U) molecules instead of one or more thymine (T) molecules, or uracil (U) molecules instead of all thymine (T) molecules. Similarly, in each example in which a tRNA contains, is essentially derived from, or consists of a nucleotide sequence containing one or more uracil (U) molecules, it is also assumed that the tRNA may contain, be essentially derived from, or consist of a nucleotide sequence containing thymine (T) molecules instead of one or more uracil (U) molecules, or thymine (T) molecules instead of all uracil (U) molecules.
[0052] [Table 2] TIFF2022554357000007.tif213151TIFF2022554357000008.tif227151TIFF2022554357000009.t if227151TIFF2022554357000010.tif227151TIFF2022554357000011.tif227151TIFF20225543570 00012.tif227151TIFF2022554357000013.tif227151TIFF2022554357000014.tif227151TIFF202 2554357000015.tif227151TIFF2022554357000016.tif227151TIFF2022554357000017.tif107151
[0053] In a particular embodiment, the tRNA comprises, essentially consists of, or comprises a nucleotide sequence, including, the nucleotide sequence shown in Table 3. In a particular embodiment, the tRNA comprises, essentially consists of, or comprises a nucleotide sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with respect to the nucleotide sequences shown in Table 3. In a particular embodiment, the tRNA is essentially composed of or consists of a nucleotide sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with a nucleotide sequence selected from SEQ ID NO: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187.
[0054] [Table 3] TIFF2022554357000019.tif227152TIFF2022554357000020.tif227152TIFF2022554357000021.tif227152TIFF2022554357000022.tif227152TIFF2022554357000023.tif227152TIFF2022554357000024.tif227152TIFF2022554357000025.tif227152TIFF2022554357000026.tif227152TIFF2022554357000027.tif227152TIFF2022554357000028.tif227152TIFF2022554357000029.tif227152TIFF2022554357000030.tif227152TIFF2022554357000031.tif227152TIFF2022554357000032.tif227152TIFF2022554357000033.tif227152TIFF2022554357000034.tif227152TIFF2022554357000035.tif227152TIFF2022554357000036.tif227152TIFF2022554357000037.tif227152TIFF2022554357000038.tif220152TIFF2022554357000039.tif227152TIFF2022554357000040.tif220152TIFF2022554357000041.tif227152TIFF2022554357000042.tif220152TIFF2022554357000043.tif227152TIFF2022554357000044.tif227152TIFF2022554357000045.tif227152TIFF2022554357000046.tif227152TIFF2022554357000047.tif227152TIFF2022554357000048.tif227152TIFF2022554357000049.tif227152TIFF2022554357000050.tif227152TIFF2022554357000051.tif227152TIFF2022554357000052.tif227152TIFF2022554357000053.tif221152TIFF2022554357000054.tif161152.
[0055] In a particular embodiment, the tRNA comprises, essentially consists of, or comprises a nucleotide sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with respect to any one of the nucleotide sequences in Tables 8 to 10.
[0056] In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence at SEQ ID NO: 6. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence at SEQ ID NO: 7. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence at SEQ ID NO: 8. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence at SEQ ID NO: 9. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence at SEQ ID NO: 11. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence at SEQ ID NO: 16. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence at SEQ ID NO: 17. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence at SEQ ID NO: 18. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence of SEQ ID NO: 19. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence of SEQ ID NO: 20. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence of SEQ ID NO: 21. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence of SEQ ID NO: 22. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence of SEQ ID NO: 35. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence of SEQ ID NO: 36. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence of SEQ ID NO: 37.In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 38. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 39. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 40. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 44. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 45. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 178. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 179. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 180. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 181. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 182. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 186. In certain embodiments, tRNA includes, essentially consists of, or comprises the nucleotide sequence with SEQ ID NO: 187.
[0057] In certain embodiments, tRNA may contain one or more mutations (e.g., nucleotide substitutions, deletions, or insertions) compared to a reference tRNA sequence (e.g., a tRNA disclosed herein). In certain embodiments, tRNA may contain, consist of, or essentially consist of a single mutation or a combination of two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more than fifteen mutations. It is assumed that tRNA may contain, consist of, or essentially consist of 1-15, 1-10, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-15, 2-10, 2-7, 2-6, 2-5, 2-4, 2-3, 3-15, 3-10, 3-7, 3-6, 3-5, or 3-4 mutations.
[0058] Sequence identity can be determined by various methods within the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. BLAST (Basic Local Alignment Search Tool) analysis (Karlin et al., (1990) PROC. NATL. ACAD. SCI. USA 87:2264-2268; Altschul (1993) J. MOL. EVOL. 36, 290-300; Altschul et al., (1997) NUCLEIC ACIDS RES. 25:3389-3402), which employs algorithms used by the programs blastp, blastn, blastx, tblastn, and tblastx, is designed for sequence similarity searches. For a discussion of the fundamentals of searching sequence databases, see Altschul et al. (1994) NATURE GENETICS 6:119-129. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm required to achieve the maximum alignment over the full length of the sequences being compared. Search parameters for histogram, description, alignment, expectation (i.e., the statistical significance threshold reporting a match to the database sequences), cutoff, matrix, and filter are the default settings. The default score matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al., (1992) PROC. NATL. ACAD. SCI. USA 89:10915-10919). The four blastn parameters can be adjusted as follows: Q=10 (gap formation penalty); R=10 (gap extension penalty); wink=1 (generates a word hit every wink-th position along the query); and gapw=16 (sets the window width to generate alignments that include gaps).An equivalent Blastp parameter setting could be Q=9;R=2;wink=1; and gapw=32. The search can also be performed using NCBI (National Center for Biotechnology Information) BLAST Advanced Option parameters (e.g., -G, Cost to widen the gap [integer]: default=5 for nucleotides / 11 for proteins; -E, Cost to extend the gap [integer]: default=2 for nucleotides / 1 for proteins; -q, Penalty for nucleotide mismatch [integer]: default=-3; -r, Reward for nucleotide match [integer]: default=1; -e, Expected value [real number]: default=10; -W, Word size [integer]: default=11 for nucleotides / 28 for megablast / 3 for proteins; -y, Drop-off for blast extension in bits (X): default=20 for blastn / 7 for others; -X, X drop-off value in bits for alignments including gaps: default=15 for all programs, not applicable to blastn; and -Z, Final X drop-off value in bits for alignments including gaps: 50 for blastn, 25 for others). ClustalW can also be used for pairwise protein alignment (default parameters may include, for example, a Blosum62 matrix and gap-opening penalty = 10 and gap-extending penalty = 0.1). Bestfit comparisons between sequences available in GCG package version 10.0 use DNA parameters GAP=50 (gap-forming penalty) and LEN=3 (gap-extending penalty), while the equivalent settings for protein comparisons are GAP=8 and LEN=2.
[0059] It is assumed that tRNA may contain one or more modifications. Exemplary modified tRNAs include acylated tRNA; alkylated tRNA; tRNA containing one or more bases other than adenine, cytosine, guanine, or uracil; tRNA covalently modified by the addition of a specific ligand or antigenic, fluorescent, affinity, reactivity, spectral, or other probe moiety; tRNA containing one or more methylated or otherwise modified ribose moieties; aa-tRNA aminoacylated with 20 non-natural amino acids, including non-natural amino acids that function as reagent carriers, specific ligands, or antigenic, fluorescent, reactivity, affinity, spectral, or other probes; or any combination of these compositions.Additionally, a single tRNA scaffold was developed by Soll et al. (1995) “tRNA: Structure, Biosynthesis, and Function,” ASM Press;El Yacoubi et al. (2012) ANNU. REV. GENET. 46:69-95;Grosjean et al. (1998) “Modification and Editing of RNA”. ASM Press;Hendrickson et al. (2004) ANNU. REV. BIOCHEM. 73:147-176, 2004;Ibba et al. (2000) ANNU. REV. BIOCHEM. 69:617-650; According to Johnson et al. (1995) COLD SPRING HARBOR SYMP. QUANT. BIOL. 60:71-82;Johnson et al. (1982) J. MOL. BIOL. 156:113-140;Crowley et al. (1994) CELL 78:61-71;Beier et al. (2001) NUCLEIC ACIDS RES. 29:4767-4782;Torres et al. (2014) TRENDS MOL. MED. 20:306-314;Bjork et al. (1987) ANNU. REV. BIOCHEM. 56:263-287;Schaffrath et al. (2017) RNA BIOL. 14(9):1209-1222;and Johansson et al. (2008) MOL. CELL. BIOL. 28(10):3301-12.
[0060] In certain embodiments, tRNAs contain naturally occurring nucleotide modifications. Naturally occurring tRNAs contain a wide variety of post-transcriptionally modified nucleotides, including, for example, one or more residues as described in Machnicka et al. (2014) RNA BIOLOGY 11(12): 1619-1629 and shown in Figure 2B. In certain embodiments, tRNAs contain 2'-O-methylguanosine or G at position 0; pseudouridine or U at position 1; 2'-O-methyladenosine, A, 2'-O-methyluridine, U, 2'-O-methylcytidine, C, 2'-O-methylguanosine or G at position 4; N2-methylguanosine or G at position 6; N2-methylguanosine or G at position 7; and 1-methyladenosine at position 9. N, A, 1-methylguanosine, G, or modified G; N2-methylguanosine or G at position 10; N4-acetylcytidine or C at position 12; pseudouridine, U, 2'-O-methylcytidine, or C at position 13; 1-methyladenosine, A, or modified A at position 14; dihydrouridine (D) or U at position 16; D or U at position 17; 2'-O-methylguanosine or G at position 18 ;3-(3-amino-3-carboxypropyl)uridine, D, or U at position 20;3-(3-amino-3-carboxypropyl)uridine, D, pseudouridine, U, or modified U at position 20a;D, pseudouridine, or U at position 20b;pseudouridine or U at position 25;pseudouridine, U, N2,N2-dimethylguanosine, N2-methylguanosine, G, or modified G at position 26;pseudouridine, U, N2,N2-dimethylguanosine, or G at position 27;pseudouridine or U at position 28;pseudouridine or U at position 30;pseudouridine or U at position 31;2'-O-methylpseudouridine, 2'-O-methyluridine, pseudouridine, U, 2'-O-methylcytidine, 3-methylcytidine, C, or modified C at position 32;Inosine (ranked 34th), A, 2-thiouridine, 2'-O-methyluridine, 5-(carboxyhydroxymethyl)uridine methyl ester, 5-carbamoylmethyluridine, 5-carboxymethylaminomethyl-2'-O-methyluridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-methoxycarbonylmethyluridine, pseudouridine, U, modified U, 2'-O-methylcytidine, 5-formyl-2'-O-methylcytidine, 5-methylcytidine, C, modified C, keuosin, mannosyl-keuosin, galactosyl-keuosin n, 2'-O-methylguanosine, or G; pseudouridine or U at position 35; pseudouridine, U, or modified U at position 36; 1-methylinosine, 2-methylthio-N6-threonylcarbamoyladenosine, N6-isopentenyladenosine, N6-methyl-N6-threonylcarbamoyladenosine, N6-threonylcarbamoyladenosine, A, modified A, 1-methylguanosine, peroxywibutosine, wibutosine, G, or modified G; pseudouridine, U, 5-methylcytidine, C, or modified C at position 38; 39th position: 1-methylpsoidouridine, 2'-O-methylpsoidouridine, 2'-O-methyluridine, pseudouridine, U, 2'-O-methylguanosine, or G; 40th position: pseudouridine, U, 5-methylcytidine, or C; 44th position: 2'-O-methyluridine, U, or modified U; e11th position: pseudouridine or U; e12th position: pseudouridine or U; e14th position: pseudouridine or U; e2nd position: 3-methylcytidine or C; 46th position: 7-methylguanosine or G; 47th position: D, U, or modified U; 48th position: D, U, 5-methylcytidine, C, or modified C; A at position 49, modified A, 5-methylcytidine, C, or modified C; pseudouridine, U, 5-methylcytidine, or C at position 50; 5,2'-O-dimethyluridine, 5-methyluridine, pseudouridine, or U at position 54; pseudouridine or U at position 55; 1-methyladenosine, A, or modified A at position 58; 2'-O-ribosyladenosine (phosphate), A, 2'-O-ribosylguanosine (phosphate), G, or modified G at position 64; pseudouridine or U at position 65;It contains one or more residues selected from the group consisting of pseudouridine, U, N2-methylguanosine, or G at position 67; pseudouridine or U at position 68; and pseudouridine, U, 5-methylcytidine, or C at position 72. A, C, G, and U represent unmodified adenine, cytosine, guanine, and uracil, respectively. The residue numbers are based on the tRNA numbering system described in Steinberg et al., (1993) NUCLEIC ACIDS RES. 21:3011-15.
[0061] In a particular embodiment, the tRNA comprises one or more nucleotide modifications selected from 5-methyluridine, 5-carbamoylmethyluridine, 5-carbamoyl-methyl-2-O-methyluridine, 5-methoxycarbonylmethyluridine, 5-methoxycarbonylmethyl-2-thiouridine, pseudouridine, dihydrouridine, 1-methyladenosine, and inosine.
[0062] II. Methods for producing tRNA It is assumed that tRNA molecules useful in carrying out the present invention (e.g., suppressor tRNA) can be produced by methods known in the art, including extracellular production by synthetic chemical methods, intracellular production by recombinant DNA methods, or purification from natural sources.
[0063] For example, DNA molecules encoding tRNA can be synthesized chemically or by recombinant DNA methods. For example, tRNA sequences can be synthesized or cloned from a library using conventional hybridization techniques or polymerase chain reaction (PCR) techniques with appropriate synthetic nucleic acid primers. The resulting tRNA-encoding DNA molecules can be ligated with other suitable nucleotide sequences, such as expression regulatory sequences, to produce a conventional gene expression construct (i.e., an expression vector) encoding tRNA. The production of defined gene constructs is common technical knowledge in the art. The nucleic acid encoding the desired tRNA can be incorporated (ligated) into an expression vector, for example, an expression vector described in the following section, and this expression vector can be introduced into host cells through conventional transfection or transformation techniques. Exemplary host cells include Escherichia coli (E. coli) cells, Chinese hamster ovary (CHO) cells, human embryonic kidney 293 (HEK293) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and bone marrow cells. Transformed host cells can be grown under conditions that enable them to express the gene encoding tRNA. Specific expression and purification conditions will vary depending on the expression system used.
[0064] Alternatively, tRNA may be chemically synthesized or purified from natural sources by methods known in the art. If tRNA is to be aminoacylated before introduction into cells or administration to a target, tRNA may be aminoacylated with the desired amino acid by any method known in the art, including chemical or enzymatic aminoacylation.
[0065] III. Expression Vectors The tRNA of interest can be expressed in cells of interest by incorporating the gene encoding the tRNA of interest into a suitable expression vector. As used herein, “expression vector” refers to a vector containing recombinant polynucleotides, which include an expression regulatory sequence functionally linked to the nucleotide sequence to be expressed. The expression vector contains sufficient cis-acting elements for expression, and other elements for expression may be supplied by the host cell or an in vitro expression system. Expression vectors include all known in the art, e.g., cosmids, plasmids (e.g., naked or contained in liposomes), retrotransposons (e.g., piggyback, sleeping beauty), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses), incorporating recombinant polynucleotides of interest.
[0066] In certain embodiments, the expression vector is a viral vector. The term “virus” is used herein to refer to an obligate intracellular parasite that does not possess a protein synthesis or energy production mechanism. Exemplary viral vectors include retroviral vectors (e.g., lentiviral vectors), adenovirus vectors, adeno-associated virus vectors, herpesvirus vectors, Epstein-Barr virus (EBV) vectors, polyomavirus vectors (e.g., monkey vacuolar virus 40 (SV40) vectors), poxvirus vectors, and pseudoviral vectors.
[0067] Viruses can be RNA viruses (having a genome composed of RNA) or DNA viruses (having a genome composed of DNA). In certain embodiments, viral vectors are DNA viral vectors. Exemplary DNA viruses include parvoviruses (e.g., adeno-associated viruses), adenoviruses, asphaviruses, herpesviruses (e.g., herpes simplex virus 1 and 2 (HSV-1 and HSV-2), Epstein-Barr virus (EBV), cytomegalovirus (CMV)), papillomaviruses (e.g., HPV), polyomaviruses (e.g., monkey vacuolar virus 40 (SV40)), and poxviruses (e.g., vaccinia virus, cowpox virus, smallpox virus, fowlpox virus, sheeppox virus, myxoma virus). In certain embodiments, viral vectors are RNA viral vectors. Exemplary RNA viruses include bunyaviruses (e.g., hantavirus), coronaviruses, flaviviruses (e.g., yellow fever virus, West Nile virus, dengue virus), hepatitis viruses (e.g., hepatitis A virus, hepatitis C virus, hepatitis E virus), influenza viruses (e.g., influenza A virus, influenza B virus, influenza C virus), measles virus, mumps virus, norovirus (e.g., Norwalk virus), poliovirus, polynuclear respiratory virus (RSV), retroviruses (e.g., human immunodeficiency virus-1 (HIV-1)), and toroviruses.
[0068] In certain embodiments, an expression vector includes a regulatory sequence or promoter functionally linked to a nucleotide sequence encoding tRNA. The term “functionally linked” describes the linking of polynucleotide elements under a functional relationship. A nucleic acid sequence is “functionally linked” when it is under a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is functionally linked to a gene if it affects the transcription of that gene. Functionally linked nucleotide sequences are typically in close proximity. However, since enhancers can usually function even if they are several kilobases away from the promoter, and intron sequences can be of varying lengths, some polynucleotide elements may be functionally linked but not directly adjacent, and may even function intrans from different alleles or even chromosomes.
[0069] tRNA genes preferably have a strong promoter that is active in various cell types. Promoters for eukaryotic tRNA genes are typically located within the structural sequence that encodes the tRNA molecule itself. Elements that regulate transcriptional activity are located in the 5' upstream region, but the length of the active transcriptional unit can be much shorter than 500 base pairs.
[0070] Further exemplary promoters that may be used include, but are not limited to, retroviral LTR, SV40 promoter, human cytomegalovirus (CMV) promoter, U6 promoter, or any other promoter (e.g., cellular promoters, including but not limited to histone, pol III, and β-actin promoters, as well as eukaryotic cellular promoters). Other viral promoters that may be used include, but are not limited to, adenovirus promoters, TK promoter, and B19 parvovirus promoter. The selection of an appropriate promoter will be apparent to those skilled in the art from the teachings contained herein.
[0071] In certain embodiments, the expression vector includes a tRNA coding sequence that encodes a tRNA that comprises, is essentially derived from, or consists of, a nucleotide sequence shown in Table 2 or Table 3. In certain embodiments, the expression vector includes a tRNA coding sequence that comprises a nucleotide sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the nucleotide sequences shown in Table 2 or Table 3, and encodes a tRNA that comprises essentially from or consists of such a sequence.
[0072] In certain embodiments, in addition to the tRNA coding sequence, the expression vector includes a nucleotide sequence corresponding to a genomic DNA sequence adjacent to the wild-type tRNA gene (i.e., a DNA sequence originating from the same genome as the wild-type tRNA gene and located 5' or 3' to the wild-type tRNA gene within that genome, for example, a DNA sequence immediately 5' or 3' to the wild-type tRNA gene within that genome). In certain embodiments, in addition to the tRNA coding sequence, the expression vector includes a nucleotide sequence corresponding to an exogenous promoter.
[0073] In certain embodiments, the expression vector contains the nucleotide sequences shown in Table 4. In certain embodiments, the expression vector contains nucleotide sequences having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the nucleotide sequences shown in Table 4. In certain embodiments, within the expression vector, the nucleotide sequences shown in Table 4 are functionally ligated to the nucleotide sequences encoding tRNA. In certain embodiments, within the expression vector, the nucleotide sequences shown in Table 4 are located at the 5' or 3' end (e.g., immediately at the 5' end or immediately at the 3' end) of the nucleotide sequences encoding tRNA. In a particular embodiment, the expression vector contains a nucleotide sequence selected from SEQ ID NO:869-888, or a nucleotide sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with respect to a sequence selected from SEQ ID NO:869-888.
[0074] In certain embodiments, the expression vector is the expression vector described in Example 8 or Example 9 of this specification.
[0075] [Table 4] TIFF2022554357000056.tif226155TIFF2022554357000057.tif220155TIFF2022554357000058.tif54155
[0076] Adeno-associated virus (AAV) vector In certain embodiments, the expression vector is an adeno-associated virus (AAV) vector. AAV is a small, non-enveloped, icosahedral virus belonging to the genus Dependparvovirus and family Parvoviridae. AAV has a single-stranded linear DNA genome of approximately 4.7 kb. AAV can infect both dividing and quiescent cells of various tissue types, and different AAV serotypes exhibit different histotropies.
[0077] AAV includes numerous serologically distinguishable types, including serotypes AAV-1 to AAV-12 and over 100 serotypes derived from non-human primates (see, for example, Srivastava (2008) J. CELL BIOCHEM., 105(1): 17-24, and Gao et al. (2004) J. VIROL., 78(12), 6381-6388). The serotypes of the AAV vectors used in this invention can be selected by those skilled in the art based on delivery efficiency, tissue tropism, and immunogenicity. For example, AAV-1, AAV-2, AAV-4, AAV-5, AAV-8, and AAV-9 may be used for delivery to the central nervous system; AAV-1, AAV-8, and AAV-9 may be used for delivery to the heart; AAV-2 may be used for delivery to the kidneys; AAV-7, AAV-8, and AAV-9 may be used for delivery to the liver; AAV-4, AAV-5, AAV-6, and AAV-9 may be used for delivery to the lungs; AAV-8 may be used for delivery to the pancreas, and AAV-2, AAV-5, and AAV-8 may be used for delivery to photoreceptor cells; AAV-1, AAV-2, AAV-4, AAV-5, and AAV-8 may be used for delivery to the retinal pigment epithelium; and AAV-1, AAV-6, AAV-7, AAV-8, and AAV-9 may be used for delivery to skeletal muscle. In certain embodiments, the AAV capsid protein includes sequences disclosed in U.S. Patent No. 7,198,951, for example, not limited to, AAV-9 (SEQ ID NO: 1-3 in U.S. Patent No. 7,198,951), AAV-2 (SEQ ID NO: 4 in U.S. Patent No. 7,198,951), AAV-1 (SEQ ID NO: 5 in U.S. Patent No. 7,198,951), AAV-3 (SEQ ID NO: 6 in U.S. Patent No. 7,198,951), and AAV-8 (SEQ ID NO: 7 in U.S. Patent No. 7,198,951). AAV serotypes identified from rhesus monkeys, for example, rh.8, rh.10, rh.39, rh.43, and rh.74, are also assumed in the present invention. In addition to the natural AAV serotypes, modified AAV capsids have been developed to improve delivery efficiency, tissue tropism, and immunogenicity.Exemplary natural and modified AAV capsids are disclosed in U.S. Patents 7,906,111, 9,493,788, and 7,198,951, and PCT Publication WO2017189964A2.
[0078] The wild-type AAV genome contains two 145-nucleotide inverted terminal repeats (ITRs) that contain signal sequences that guide AAV replication, genome capsidation, and integration. In addition to the ITRs, three AAV promoters, p5, p19, and p40, promote the expression of two open reading frames encoding the rep and cap genes. Along with differential splicing of a single AAV intron, the two rep promoters generate four rep proteins (Rep 78, Rep 68, Rep 52, and Rep 40) from the rep gene. The rep proteins are responsible for genome replication. The cap gene is expressed from the p40 promoter and encodes three capsid proteins (VP1, VP2, and VP3), which are splice variants of the cap gene. These proteins form the capsid of the AAV particle.
[0079] Since cis-acting signals for replication, capsidation, and integration are contained within the ITR, part or all of the 4.3 kb of internal genome can be replaced with exogenous DNA, such as an expression cassette for an exogenous gene of interest. Thus, in certain embodiments, the AAV vector comprises a genome containing expression cassettes for exogenous genes adjacent to the 5' ITR and 3' ITR. The ITR may be of the same serotype as the capsid or a derivative thereof. Alternatively, the ITR may be of a different serotype than the capsid, thereby generating a pseudo-AAV. In certain embodiments, the ITR is derived from AAV-2. In certain embodiments, the ITR is derived from AAV-5. At least one of the ITRs may be modified to mutate or remove a terminal resolution site, thereby generating a self-complementary AAV vector.
[0080] To generate AAV vectors, rep and cap proteins can be provided intrans, for example, on a plasmid. Host cell lines that allow AAV replication must express the rep and cap genes, an expression cassette adjacent to the ITR, and helper functions provided by a helper virus, such as adenovirus genes E1a, E1b55K, E2a, E4orf6, and VA (Weitzman et al., Adeno-associated virus biology. Adeno-Associated Virus: Methods and Protocols, pp. 1-23, 2011). Methods for generating and purifying AAV vectors are described in detail (see, for example, Mueller et al., (2012) CURRENT PROTOCOLS IN MICROBIOLOGY, 14D.1.1-14D.1.21, Production and Discovery of Novel Recombinant Adeno-Associated Viral Vectors). Numerous cell types, including HEK293 cells, COS cells, HeLa cells, BHK cells, Vero cells, and insect cells, are suitable for AAV vector production (see, for example, U.S. Patents 6,156,303, 5,387,484, 5,741,683, 5,691,176, 5,688,676, and 8,163,543, U.S. Patent Publication 20020081721, and PCT Publications WO00 / 47757, WO00 / 24916, and WO96 / 17947). AAV vectors are typically produced in these cell types by a single plasmid containing an expression cassette adjacent to the ITR, and one or more additional plasmids providing additional AAV and helper virus genes.
[0081] In this invention, any serotype of AAV may be used. Similarly, any adenovirus type may be used, and it is assumed that those skilled in the art will be able to identify AAV and adenovirus types suitable for the production of their desired recombinant AAV vector (rAAV). AAV particles may be purified, for example, by affinity chromatography, iodixanol gradient, or CsCl gradient.
[0082] AAV vectors can be 4.7 kb in size, or have single-stranded genomes larger or smaller than 4.7 kb, including a large oversized genome of 5.2 kb or a small one of 3.0 kb. Therefore, if the exogenous gene of interest to be expressed from the AAV vector is small, the AAV genome may contain a stuffer sequence. Furthermore, the vector genome may be substantially self-complementary, thereby enabling rapid expression within cells. In certain embodiments, the genome of a self-complementary AAV vector includes: a 5' ITR; a first nucleic acid sequence containing a promoter and / or enhancer functionally linked to the coding sequence of the gene of interest; a modified ITR without functional terminal degradation sites; a second nucleic acid sequence complementary or substantially complementary to the first nucleic acid sequence; and a 3' ITR. AAVs containing all types of genomes are suitable for use in the methods of the present invention.
[0083] Non-exclusive examples of AAV vectors include pAAV-MCS (Agilent Technologies), pAAVK-EF1α-MCS (System Bio catalog #AAV502A-1), and pAAVK-EF1α-MCS1-CMV-MCS2 (System Bio catalog #AAV503A-1), pAAV-ZsGreen1 (Clontech catalog #6231), pAAV-MCS2 (Addgene plasmid #46954), AAV-Stuffer (Addgene plasmid #106248), pAAVscCBPIGpluc (Addgene plasmid #35645), AAVS1_Puro_PGK1_3xFLAG_Twin_Strep (Addgene plasmid #68375), pAAV-RAM-d2TTA::TRE-MCS-WPRE-pA (Addgene plasmid #63931), pAAV-UbC (Addgene plasmid #62806), pAA This includes VS1-P-MCS (Addgene plasmid #80488), pAAV-Gateway (Addgene plasmid #32671), pAAV-Puro_siKD (Addgene plasmid #86695), pAAVS1-Nst-MCS (Addgene plasmid #80487), pAAVS1-Nst-CAG-DEST (Addgene plasmid #80489), pAAVS1-P-CAG-DEST (Addgene plasmid #80490), pAAVf-EnhCB-lacZnls (Addgene plasmid #35642), and pAAVS1-shRNA (Addgene plasmid #82697). These vectors can be modified to be suitable for therapeutic use. For example, the exogenous gene of interest may be inserted into a multicloning site, and a selection marker (e.g., a gene encoding puro or a fluorescent protein) may be removed or replaced with another (same or different) exogenous gene of interest.Further examples of AAV vectors are disclosed in U.S. Patents 5,871,982, 6,270,996, 7,238,526, 6,943,019, 6,953,690, 9,150,882, and 8,298,818, U.S. Patent Publication 2009 / 0087413, and PCT Publications WO2017075335A1, WO2017075338A2, and WO2017201258A1.
[0084] In certain embodiments, the expression vector is an AAV vector capable of targeting the nervous system, such as the central nervous system, in a target, such as a human target. Exemplary AAV vectors capable of targeting the nervous system include the AAV9 variant AAV-PHP.B (see, e.g., Deverman et al. (2016) NAT. BIOTECHNOL. 34(2):204-209), AAV-AS (see, e.g., Choudhury et al. (2016) MOL. THER. 24:726-35), and AAV-PHP.eB (see, e.g., Chan et al. (2017) NAT. NEUROSCI. 20:1172-79). Further exemplary AAV-based strategies for targeting the nervous system are described in Bedrook et al. (2018) ANNU REV NEUROSCI. 41:323-348. In a particular embodiment, the AAV vector is the AAV-PHP.eB vector.
[0085] lentiviral vectors In certain embodiments, viral vectors can be retroviral vectors. Examples of retroviral vectors include Moloney's mouse leukemia virus vectors, splenic necrosis virus vectors, and vectors derived from retroviruses such as Rous sarcoma virus, Harvey sarcoma virus, avian leukemia virus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus. Retroviral vectors are useful as agents that mediate retroviral gene transfer into eukaryotic cell organisms.
[0086] In certain embodiments, retroviral vectors are lentiviral vectors. Exemplary lentiviral vectors include vectors derived from human immunodeficiency virus-1 (HIV-1), human immunodeficiency virus-2 (HIV-2), simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), Jembrana disease virus (JDV), equine infectious anemia virus (EIAV), and canine arthritis-encephalitis virus (CAEV).
[0087] Retroviral vectors are typically constructed by removing most of the sequences encoding the virus's structural genes and replacing them with the gene of interest. Often, structural genes (e.g., gag, pol, and env) are removed from the retroviral backbone using genetic engineering techniques known in the art. Thus, minimal retroviral vectors include a 5'-to-3' long-terminal repeat (LTR), a packaging signal, an optional exogenous promoter and / or enhancer, the exogenous gene of interest, and a 3' LTR. If an exogenous promoter is not provided, gene expression is driven by the 5' LTR, which is a weak promoter and requires the presence of Tat to activate expression. For the production of lentiviruses, the structural genes can be supplied in a separate vector, thereby making the virions produced replication-deficient. In detail, with respect to lentiviruses, the packaging system may include a single packaging vector encoding the Gag, Pol, Rev, and Tat genes, and a third separate vector encoding the envelope protein Env (usually VSV-G due to its broad infectivity). To improve the safety of the packaging system, the packaging vector may be split so that Rev is expressed from one vector and Gag and Pol from another. Tat may also be removed from the packaging system by using a retroviral vector containing a chimeric 5' LTR in which the U3 region of the 5' LTR is replaced with a heterologous regulatory element.
[0088] Genes can be incorporated into the proviral scaffold in various common ways. The most direct construct is one in which the structural genes of a retroviral are replaced by a single gene transcribed under the control of a viral regulatory sequence within the LTR. Retroviral vectors have also been constructed that can introduce two or more genes into target cells. Typically, in such vectors, one gene is under the regulatory control of the viral LTR, while the second gene is either expressed from a spliced message or under the regulation of its own internal promoter.
[0089] Therefore, the new genes are flanked by 5' and 3' LTRs, respectively, which function to promote the transcription and polyadenylation of virion RNA. The term “long-terminal repeat” or “LTR” refers to a domain of base pairs located at the end of retroviral DNA, which in their natural sequence are serial repeats and contain U3, R, and U5 regions. LTRs typically provide functions essential for retroviral gene expression (e.g., promotion, initiation, and polyadenylation of gene transcripts) and viral replication. LTRs contain many regulatory signals, including transcriptional regulatory elements, polyadenylation signals, and sequences required for replication and integration of the viral genome. The U3 region contains enhancer and promoter elements. The U5 region is the sequence between the primer binding site and the R region and contains the polyadenylation sequence. The R (repeat) region flanks the U3 and U5 regions. In certain embodiments, the R region contains a transactivation response (TAR) gene element that interacts with a transactivator (tat) gene element to enhance viral replication. This element is not required in embodiments where the U3 region of the 5' LTR is replaced by a heterogeneous promoter.
[0090] In certain embodiments, the retroviral vector comprises a modified 5' LTR and / or 3' LTR. Modification of the 3' LTR is often performed to improve the safety of the lentiviral or retroviral system by conferring replication deficiency to the virus. In certain embodiments, the retroviral vector is a self-inactivating (SIN) vector. As used herein, a SIN retroviral vector represents a replication-deficient retroviral vector in which the U3 region of the 3' LTR is modified (e.g., by deletion or substitution) to prevent viral transcription beyond the first round of viral replication. This is because, during viral replication, the U3 region of the 3' LTR is used as a template for the U3 region of the 5' LTR, and therefore viral transcripts cannot be produced without the U3 enhancer promoter. In further embodiments, the 3' LTR is modified such that the U5 region is replaced, for example, with an ideal polyadenylated sequence. It should be noted that modifications to LTRs, e.g., to the 3' LTR, 5' LTR, or both the 3' and 5' LTRs, are also assumed to be useful in the implementation of the present invention.
[0091] In certain embodiments, the U3 region of the 5' LTR is replaced with a heterologous promoter that drives transcription of the viral genome during viral particle production. Examples of heterologous promoters that may be used include, for example, the Simian virus 40 (SV40) (e.g., early or late), cytomegalovirus (CMV) (e.g., very early), Moloney's mouse leukemia virus (MoMLV), Rous sarcoma virus (RSV), and herpes simplex virus (HSV) (thymidine kinase) promoter. Typical promoters can drive high levels of transcription in a Tat-independent manner. This substitution reduces the likelihood of recombination that generates a replicable virus because the complete U3 sequence is no longer present in the viral production system.
[0092] Adjacent to the 5' LTR are sequences required for reverse transcription of the genome (tRNA primer binding site) and for efficient packaging of viral RNA into particles (Psi site). As used herein, the terms “packaging signal” or “packaging sequence” refer to sequences located within the retroviral genome that are required for capsidation of the retroviral RNA strand during viral particle formation (see, e.g., Clever et al., 1995 J. VIROLOGY, 69(4):2101-09). The packaging signal may be the minimal packaging signal (also called the psi [Ψ] sequence) required for capsidation of the viral genome.
[0093] In certain embodiments, retroviral vectors (e.g., lentiviral vectors) further include FLAPs. As used herein, the term "FLAP" refers to a nucleic acid whose sequence includes the central polyprint lactate and central termination sequences (cPPT and CTS) of a retrovirus, e.g., HIV-1 or HIV-2. Suitable FLAP elements are described in U.S. Patent No. 6,682,907 and Zennou et al. (2000) CELL, 101:173. During reverse transcription, the central start of the forward DNA in the cPPT and the central termination in the CTS form a triple-stranded DNA structure: a central DNA flap. Although we do not wish to be bound by any theory, the DNA flap may act as a cis-acting determinant of nuclear transport of the lentiviral genome and / or increase the titer of the virus. In certain embodiments, the retroviral vector backbone includes one or more FLAP elements upstream or downstream of the heterologous gene of interest within the vector. For example, in certain embodiments, the transport plasmid includes FLAP elements. In one embodiment, the vector of the present invention comprises a FLAP element isolated from HIV-1.
[0094] In certain embodiments, retroviral vectors (e.g., lentiviral vectors) further include export elements. In one embodiment, a retroviral vector includes one or more export elements. The term “export element” refers to a cis-acting post-transcriptional regulatory element that regulates the transport of RNA transcripts from the nucleus to the cytoplasm of a cell. Examples of RNA export elements include, but are not limited to, human immunodeficiency virus (HIV) RREs (see, e.g., Cullen et al., (1991) J. VIROL. 65: 1053; and Cullen et al., (1991) CELL 58: 423) and hepatitis B virus post-transcriptional regulatory elements (HPREs). Generally, RNA export elements are located within the 3' UTR of a gene and may be inserted as one or more copies.
[0095] In certain embodiments, retroviral vectors (e.g., lentiviral vectors) further include post-transcriptional regulatory elements. Various post-transcriptional regulatory elements, such as the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE; see Zufferey et al., (1999) J. VIROL., 73:2886); the post-transcriptional regulatory element present in hepatitis B virus (HPRE) (Huang et al., MOL. CELL. BIOL., 5:3864); and others (Liu et al., (1995), GENES DEV., 9:1766), can increase the expression of heterologous nucleic acids. Post-transcriptional regulatory elements are typically located at the 3' end of the heterologous nucleic acid sequence. This configuration synthesizes an mRNA transcript in which the 5' portion contains the heterologous nucleic acid coding sequence and the 3' portion contains the post-transcriptional regulatory element sequence. In certain embodiments, the vectors of the present invention lack or do not contain post-transcriptional regulatory elements, such as WPRE or HPRE, because in some examples these elements increase the risk of cell transformation and / or substantially or significantly increase the amount of mRNA transcript or mRNA stability. Accordingly, in certain embodiments, the vectors of the present invention lack or do not contain WPRE or HPRE as an additional safety measure.
[0096] Elements that lead the efficient termination and polyadenylation of heterologous nucleic acid transcripts increase the expression of heterologous genes. Transcription termination signals are typically found downstream of polyadenylation signals. Therefore, in certain embodiments, retroviral vectors (e.g., lentiviral vectors) further include polyadenylation signals. The terms “polyadenylation signal” or “polyadenylation sequence,” as used herein, mean the DNA sequence that leads both the termination and polyadenylation of the RNA transcript newly formed by RNA polymerase H. Since transcripts lacking polyadenylation signals are unstable and rapidly degraded, efficient polyadenylation of recombinant transcripts is desirable. Specific examples of polyadenylation signals that can be used in the vectors of the present invention include ideal polyadenylation sequences (e.g., AATAAA, ATTAAA AGTAAA), bovine growth hormone polyadenylation sequences (BGHpA), rabbit β-globin polyadenylation sequences (rβgpA), or other suitable heterologous or endogenous polyadenylation sequences known in the art.
[0097] In certain embodiments, the retroviral vector further includes an insulator element. The insulator element may contribute to the protection of retroviral expression sequences, such as therapeutic genes, from integration site effects (i.e., positional effects; see, e.g., Burgess-Beusse et al., (2002) PROC. NATL. ACAD. SCI., USA, 99:16433; and Zhan et al., 2001, HUM. GENET., 109:471), which may be mediated by cis-acting elements present in the genomic DNA and result in the unregulated expression of the transferred sequence. In certain embodiments, the retroviral vector includes an insulator element in one or both LTRs or at another location within the region of the vector integrated into the cellular genome. Insulators suitable for use in the present invention include, but are not limited to, chicken β-globin insulators (see Chung et al., (1993). CELL 74:505; Chung et al., (1997) PROC. NATL. ACAD. SCI., USA 94:575; and Bell et al., 1999. CELL 98:387). Examples of insulator elements include, but are not limited to, insulators derived from the β-globin locus, e.g., chicken HS4.
[0098] Non-exclusive examples of lentiviral vectors include pLVX-EF1alpha-AcGFP1-C1 (Clontech catalog #631984), pLVX-EF1alpha-IRES-mCherry (Clontech catalog #631987), pLVX-Puro (Clontech catalog #632159), pLVX-IRES-Puro (Clontech catalog #632186), pLenti6 / V5-DEST(trademark) (Thermo Fisher), and pLenti6.2 / V5-DEST(trademark) (Thermo Fisher). Fisher), pLKO.1 (Addgene plasmid #10878), pLKO.3G (Addgene plasmid #14748), pSico (Addgene plasmid #11578), pLJM1-EGFP (Addgene plasmid #19319), FUGW (Addgene plasmid #14883), pLVTHM (Addgene plasmid #12247), pLVUT-tTR-KRAB (Addgene plasmid #11651), pLL3.7 (Addgene plasmid #11795), pLB (Addgene plasmid #11619), pWPXL (Addgene plasmid #12257), pWPI (Addgene plasmid #12254), EF.CMV.RFP (Addgene plasmid #17619), pLenti CMV Puro These include DEST (Addgene plasmid #17452), pLenti-puro (Addgene plasmid #39481), pULTRA (Addgene plasmid #24129), pLX301 (Addgene plasmid #25895), pHIV-EGFP (Addgene plasmid #21373), pLV-mCherry (Addgene plasmid #36084), pLionII (Addgene plasmid #1730), and pInducer10-mir-RUP-PheS (Addgene plasmid #44011). These vectors can be modified to be suitable for therapeutic use. For example, a selection marker (e.g., puro, EGFP, or mCherry) can be removed or replaced with an exogenous gene of a second interest.Further examples of lentiviral vectors include U.S. Patent Nos. 7,629,153, 7,198,950, 8,329,462, 6,863,884, 6,682,907, 7,745,179, 7,250,299, 5,994,136, and 6,287,814. This information is disclosed in publications No. 6,013,516, No. 6,797,512, No. 6,544,771, No. 5,834,256, No. 6,958,226, No. 6,207,455, No. 6,531,123, and No. 6,352,694, as well as in PCT Publication WO2017 / 091786.
[0099] Adenovirus vector In certain embodiments, a viral vector may be an adenovirus vector. Adenoviruses are medium-sized (90–100 nm), non-enveloped (naked), icosahedral viruses consisting of a nucleocapsid and a double-stranded linear DNA genome. The term “adenovirus” refers to any virus of the genus Adenobilidae, including but not limited to human, bovine, sheep, horse, dog, pig, mouse, and monkey adenovirus subgenera. Typically, an adenovirus vector is produced by introducing one or more mutations (e.g., deletions, insertions, or substitutions) into the adenovirus genome of an adenovirus to allow for the insertion of non-native nucleic acid sequences, for example, for gene transfer.
[0100] Human adenoviruses can be used as a source of adenovirus genomes for adenovirus vectors. For example, the adenovirus may be from subgroup A (e.g., serotypes 12, 18, and 31), subgroup B (e.g., serotypes 3, 7, 11, 14, 16, 21, 34, 35, and 50), subgroup C (e.g., serotypes 1, 2, 5, and 6), subgroup D (e.g., serotypes 8, 9, 10, 13, 15, 17, 19, 20, 22-30, 32, 33, 36-39, and 42-48), subgroup E (e.g., serotype 4), subgroup F (e.g., serotypes 40 and 41), an unclassified serogroup (e.g., serotypes 49 and 51), or any other adenovirus serogroup or serotype. Adenovirus serotypes 1–51 are available from the American Type Culture Collection (ATCC, Manassas, Virginia). Non-group C adenovirus vectors, methods for constructing non-group C adenovirus vectors, and methods for using non-group C adenovirus vectors are disclosed, for example, in U.S. Patents 5,801,030, 5,837,511, and 5,849,561, and PCT Publications WO1997 / 012986 and WO1998 / 053087.
[0101] Non-human adenoviruses (e.g., ape, monkey, bird, dog, sheep, or bovine adenoviruses) can be used to construct adenovirus vectors (i.e., as a source of adenovirus genome for adenovirus vectors). For example, adenovirus vectors may be based on primate adenoviruses, including those from both New World and Old World monkeys (see, e.g., Virus Taxonomy: VHIth Report of the International Committee on Taxonomy of Viruses (2005)). Phylogenetic analyses of adenoviruses infecting primates are disclosed, e.g., Roy et al. (2009) PLOS PATHOG. 5(7):e1000503. Gorilla adenoviruses can be used as a source of adenovirus genome for adenovirus vectors. Gorilla adenoviruses and adenovirus vectors are described, for example, in PCT Publications WO2013 / 052799, WO2013 / 052811, and WO2013 / 052832. Adenovirus vectors may also include combinations of subtimes and thus may be "chimeric" adenovirus vectors.
[0102] Adenovirus vectors can be replicable, conditionally replicable, or replication-deficient. A replicable adenovirus vector can replicate in typical host cells, i.e., cells that can typically be infected by adenovirus. A conditionally replicable adenovirus vector is an adenovirus vector engineered to replicate under specific conditions. For example, a gene function essential for replication, such as a gene function encoded by the adenovirus early region, may be functionally linked to an inducible, repressive, or tissue-specific transcriptional regulatory sequence, such as a promoter. Conditionally replicable adenovirus vectors are further described in U.S. Patent No. 5,998,205. A replication-deficient adenovirus vector is an adenovirus vector that requires the completion of one or more gene functions or regions of the adenovirus genome required for replication, as a result of the absence of one or more gene functions or regions essential for replication, causing the adenovirus vector to not replicate in typical host cells, particularly human cells, that it infects.
[0103] Preferably, the adenovirus vector is replication-deficient, and replication-deficient adenovirus vectors require the complementation of gene function essential for replication in at least one of one or more regions of the adenovirus genome for proliferation (e.g., to form adenovirus vector particles). The adenovirus vector may be deletion-deficient with respect to only the early region of the adenovirus genome (i.e., E1-E4 region), only the late region of the adenovirus genome (i.e., L1-L5 region), one or more gene function essential for replication in both the early and late regions of the adenovirus genome, or all adenovirus genes (i.e., high-capacity adenovector (HC-Ad)). See, for example, Morsy et al. (1998) PROC. NATL. ACAD. SCI. USA 95: 965-976, Chen et al. (1997) PROC. NATL. ACAD. SCI. USA 94: 1645-1650, and Kochanek et al. (1999) HUM. GENE THER. 10(15):2451-9. Examples of replication-deficient adenovirus vectors are disclosed in U.S. Patents 5,837,511, 5,851,806, 5,994,106, 6,127,175, 6,482,616, and 7,195,896, as well as in PCT Publications WO1994 / 028152, WO1995 / 002697, WO1995 / 016772, WO1995 / 034671, WO1996 / 022378, WO1997 / 012986, WO1997 / 021826, and WO2003 / 022311.
[0104] The replication-deficient adenovirus vector of the present invention can be produced in complementary cell lines that provide, at appropriate levels, gene functions that are absent in the replication-deficient adenovirus vector but are necessary for viral replication, in order to generate a high-titer viral vector stock. Such complementary cell lines are known and include, but are not limited to, 293 cells (as described in, e.g., Graham et al. (1977) J. GEN. VIROL. 36: 59-72), PER.C6 cells (as described in, e.g., PCT Publication WO1997 / 000326 and U.S. Patents 5,994,128 and 6,033,908), and 293-ORF6 cells (as described in, e.g., PCT Publication WO1995 / 034671 and Broough et al. (1997) J. VIROL. 71: 9206-9213). Other suitable complementary cell lines for producing the replication-deficient adenovirus vector of the present invention include complementary cell lines prepared for growing adenovirus vectors whose expression encodes a transgene that inhibits viral growth in host cells (see, for example, U.S. Patent Publication 2008 / 0233650). Further suitable complementary cells are described, for example, U.S. Patents 6,677,156 and 6,682,929, and PCT Publication WO2003 / 020879. Formulations for adenovirus vector-containing compositions are further described, for example, U.S. Patents 6,225,289 and 6,514,943, and PCT Publication WO2000 / 034444.
[0105] Further exemplary adenovirus vectors and / or methods for generating or propagating adenovirus vectors are described in U.S. Patents No. 5,559,099, No. 5,837,511, No. 5,846,782, No. 5,851,806, No. 5,994,106, No. 5,994,128, No. 5,965,541, No. 5,981,225, No. 6,040,174, No. 6,020,191, No. 6,083,716, No. 6,113,913, No. 6,303,362, No. 7,067,310, and No. 9,073,980.
[0106] Commercially available adenovirus vector systems include the ViraPower® adenovirus expression system from Thermo Fisher Scientific, the AdEasy® adenovirus vector system from Agilent Technologies, and the Adeno-X® expression system 3 from Takara Bio USA, Inc.
[0107] Production of viral vectors Methods for producing viral vectors are known in the art. Typically, the virus of interest is produced in suitable host cells using conventional techniques, including transfection or culture of infected host cells under appropriate conditions that enable the production of infectious viral particles. The nucleic acid encoding the viral gene and / or tRNA may be incorporated into a plasmid and introduced into host cells through conventional transfection or transformation techniques. Exemplary host cells suitable for the production of the disclosed virus include human cell lines such as HeLa, Hela-S3, HEK293, 911, A549, HER96, or PER-C6 cells. Specific production and purification conditions will vary depending on the virus and production system used.
[0108] In certain embodiments, producer cells may be administered directly to the target, while in other embodiments, after production, infectious virus particles are recovered from the culture and optionally purified. Typical purification steps may include plaque purification, centrifugation (e.g., cesium chloride gradient centrifugation), clarification, enzymatic treatment (e.g., benzonase or protease treatment), and chromatography (e.g., ion exchange chromatography or filtration).
[0109] IV. Pharmaceutical Compositions For therapeutic use, tRNA and / or expression vectors are preferably combined with a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable," as used herein, means a compound, substance, composition, and / or dosage form that, within reasonable medical judgment and under a reasonable benefit / risk ratio, is suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications.
[0110] The term "pharmaceutically acceptable carrier," as used herein, refers to buffers, carriers, and excipients suitable for use in contact with human and animal tissues under a reasonable benefit / risk ratio, without excessive toxicity, irritation, allergic reactions, or other problems or complications. pharmaceutically acceptable carriers include any standard pharmaceutically acceptable carrier, e.g., phosphate-buffered saline, water, emulsions (e.g., oil / water or water / oil emulsions), and various types of wetting agents. Compositions may also include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA
[1975] . pharmaceutically acceptable carriers include buffers, solvents, dispersions, coatings, isotonic agents, and absorption retarders suitable for pharmaceutically active substances. The use of such media and agents for pharmaceutically active substances is known in the art.
[0111] In certain embodiments, the pharmaceutical composition may contain, for example, formulation materials for altering, maintaining, or preserving the composition's pH, osmolality, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, absorption or permeability.In such embodiments, suitable formulation materials include amino acids (e.g., glycine, glutamine, asparagine, arginine, or lysine); antimicrobial agents; antioxidants (e.g., ascorbic acid, sodium sulfite, or sodium bisulfite); buffering agents (e.g., borates, bicarbonates, Tris-HCl, citrates, phosphates, or other organic acids); bulk agents (e.g., mannitol or glycine); chelating agents (e.g., ethylenediaminetetraacetic acid (EDTA)); complexing agents (e.g., caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (e.g., glucose, mannose, or dextrin); proteins (e.g., serum albumin, gelatin, or immunoglobulin); colorants, flavorings, and diluents; emulsifiers; hydrophilic polymers (e.g., polyvinylpyrrolidone); low molecular weight polypeptides; and salt-forming counterions. For example, sodium; preservatives (for example, benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide); solvents (for example, glycerin, propylene glycol, or polyethylene glycol); sugar alcohols (for example, mannitol or sorbitol); suspending agents; surfactants or wetting agents (for example, Pluronic acid, PEG, sorbitan esters, polysorbates, for example, polysorbate 20, polysorbate, Triton, tromethamine, lecithin, cholesterol, tyroxapole); stability enhancers (for example, sucrose or sorbitol); isotonic enhancers (for example, alkali metal halides, preferably sodium chloride or potassium chloride, mannitol, sorbitol); delivery vehicles; diluents; excipients and / or pharmaceutical adjuvants (see Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990)).
[0112] In certain embodiments, the pharmaceutical composition may contain nanoparticles, e.g., polymer nanoparticles, liposomes, or micelles (see Anselmo et al. (2016) BIOENG. TRANSL. MED. 1: 10-29). In certain embodiments, the composition does not contain (or substantially does not contain, e.g., the composition contains less than 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of) nanoparticles or aminolipid delivery compounds, e.g., as described in U.S. Patent Publication No. 2017 / 0354672. In certain embodiments, the tRNA or expression vector introduced into cells or administered to a target is neither conjugated nor bound to another part, e.g., carrier particles, e.g., aminolipid particles. As used herein, the term “conjugate,” when used in reference to two or more parts, means that these parts are physically joined or connected to one another, either directly or through one or more additional parts acting as linkers, forming a structure that is stable enough to maintain the physical bond between the parts under the conditions under which the structure is used, e.g., physiological conditions. Typically, these parts are joined either by one or more covalent bonds or by mechanisms involving specific bonding. Alternatively, a sufficient number of weak interactions may provide sufficient stability for the parts to maintain the physical bond.
[0113] In certain embodiments, the pharmaceutical composition may contain sustained or controlled delivery formulations. Techniques for formulating sustained or controlled delivery means, such as liposome carriers, biocorrosive microparticles or porous beads and depot injections, are also known to those skilled in the art. Sustained-release preparations may include, for example, molded articles, such as films or microcapsules, porous polymer microparticles, or semipermeable polymer matrices. Sustained-release matrices may include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma-ethyl-L-glutamate, poly(2-hydroxyethyl methacrylate), ethylene vinyl acetate, or poly-D(-)-3-hydroxybutyric acid. The sustained-release composition may also contain liposomes, which can be prepared by any various methods known in the art.
[0114] Pharmaceutical compositions containing tRNA and / or expression vectors disclosed herein may be provided in dosage unit form and may be prepared by any suitable method. The pharmaceutical compositions should be formulated to be compatible with their intended route of administration. Examples of routes of administration include intravenous (IV), intradermal, inhalation, transdermal, topical, transmucosal, intrathecal, and rectal administration. In certain embodiments, tRNA and / or expression vectors are administered intrathecally. In certain embodiments, tRNA and / or expression vectors are administered by injection. Useful formulations may be prepared by methods known in the pharmaceutical field. See, for example, Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990). Formulas suitable for parenteral administration include sterile diluents, such as sterile water for injection, physiological saline solution, fixative oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents; antimicrobial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium sulfite; chelating agents, such as EDTA; buffering agents, such as acetates, citrates, or phosphates; and isotonic modifiers, such as sodium chloride or dextrose.
[0115] For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL® (BASF, Parsippany, NJ), or phosphate-buffered saline (PBS). The carrier should be stable under manufacturing and storage conditions and protected from microorganisms. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, polyethylene glycol, and liquid polyethylene glycol), or suitable mixtures thereof.
[0116] In general, any method of delivering nucleic acid molecules can be adapted for use with tRNA (see, for example, Akhtar et al. (1992) TRENDS CELL. BIOL. 2(5):139-144 and PCT Publication WO94 / 02595). tRNA can be modified to prevent rapid degradation by endo- and exonucleases in vivo, or it can be delivered using drug delivery systems. tRNA molecules can be modified by chemical conjugation to lipophilic groups, such as cholesterol, to enhance cellular uptake and prevent degradation. tRNA molecules can also be conjugated to aptamers or otherwise bound. tRNA can also be delivered using drug delivery systems, such as nanoparticles, dendrimers, polymers, liposomes, or cationic delivery systems. Positively charged cationic delivery systems promote the binding of (negatively charged) tRNA molecules and enhance interaction with negatively charged cell membranes to enable efficient uptake of tRNA by cells. Cationic lipids, dendrimers, or polymers may either bind to RNA, such as tRNA, or be induced to form vesicles or micelles surrounding RNA (see, e.g., Kim et al. (2008) JOURNAL OF CONTROLLED RELEASE 129(2):107-116). Methods for constructing and administering cationic RNA complexes are well within the capabilities of those skilled in the art (see, e.g., Sorensen et al. (2003) J. MOL. BIOL 327:761-766; Verma et al. (2003) CLIN. CANCER RES. 9:1291-1300; Arnold et al. (2007) J. HYPERTENS. 25:197-205).Some non-limiting examples of drug delivery systems useful for systemic delivery of RNA, such as tRNA, include DOTAP (Sorensen et al. (2003) hereafter; Verma et al. (2003) hereafter), oligofectamine, solid-phase nucleic acid lipid particles (Zimmermann et al. (2006) NATURE 441:111-114), cardiolipin (Chien et al. (2005) CANCER GENE THER. 12:321-328; Pal et al. (2005) INT J. ONCOL. 26:1087-1091), polyethyleneimine (Bonnet et al. (2008) PHARM. RES. 25(12):2972-82; Aigner (2006) J. BIOMED. BIOTECHNOL. 71659), and Arg-Gly-Asp(RGD) peptide (Liu This includes (2006) MOL. PHARM. 3:472-487), and polyamidoamines (Tomalia et al. (2007) BIOCHEM. SOC. TRANS. 35:61-67; Yoo et al. (1999) PHARM. RES. 16:1799-1804). In certain embodiments, tRNA forms a complex with cyclodextrin for systemic administration. Methods and pharmaceutical compositions for administering RNA and cyclodextrin can be found in U.S. Patent No. 7,427,605.
[0117] Pharmaceutical preparations are preferably sterile. Sterilization can be achieved by any suitable method, for example, filtration through a sterile filtration membrane. If the composition is lyophilized, sterilization by filtration can be performed before or after lyophilization and reconstitution.
[0118] The compositions described herein may be administered topically or systemically. Administration will typically be parenteral. In a preferred embodiment, the pharmaceutical composition will be administered subcutaneously, and in a more preferred embodiment, intravenously. Preparations for parenteral administration include sterile, aqueous or non-aqueous solutions, suspensions, and emulsions.
[0119] Generally, the therapeutically effective amount of the active ingredient, such as tRNA and / or the expression vector, is in the range of 0.1 mg / kg to 100 mg / kg, for example, 1 mg / kg to 100 mg / kg, 1 mg / kg to 10 mg / kg. In certain embodiments, the therapeutically effective amount of the viral expression vector is 10 2 to 10 15 plaque forming units (pfu), for example, 10 2 to 10 10 , 10 2 to 10 5 , 10 5 to 10 15 , 10 5 to 10 10 or 10 10 to 10 15 pfu. The amount administered may depend on variables such as the type and extent of the disease or condition being treated, the general health of the patient, the in vivo efficacy of the antibody, the pharmaceutical formulation, and the route of administration. The initial dose may be increased above the upper limit level in order to rapidly achieve the desired blood level or tissue level. Alternatively, the initial dose may be less than its optimal amount and the daily dose may be gradually increased during the course of treatment. The human dose can be optimized in a conventional Phase I dose escalation study designed, for example, to be carried out at 0.5 mg / kg to 20 mg / kg. The dosing frequency can vary depending on factors such as the route of administration, the dosage, the serum half-life, and the disease being treated. Exemplary dosing frequencies are once daily, once a week and once every two weeks. The preferred route of administration is parenteral, for example, intravenous infusion. In certain embodiments, the polypeptide and / or multimeric protein is lyophilized and then reconstituted with buffered saline at the time of administration.
[0120] In certain embodiments, the tRNA or expression vector is neither conjugated nor bound to another part, such as a carrier particle, such as an aminolipid particle. In certain embodiments, the tRNA or expression vector is introduced into cells or administered to a subject in a dosage form lacking nanoparticles. In certain embodiments, the tRNA or expression vector is introduced into cells or administered to a subject in a dosage form lacking an aminolipid delivery compound, such as described in U.S. Patent Publication 2017 / 0354672.
[0121] V. Therapeutic Use The compositions and methods disclosed herein may be used to treat immature stop codon (PTC)-mediated disorders in a subject. As used herein, the term “PTC-mediated disorder” refers to a disorder that is mediated, enhanced, aggravated, or otherwise facilitated by a PTC in a gene, or a disorder related to a PTC in a gene.
[0122] The present invention provides a method for treating PTC-mediated injury in subjects where such treatment is needed. The method comprises administering to a subject an effective amount of tRNA and / or expression vector, for example, the tRNA and / or expression vector disclosed herein, either alone or in combination with another therapeutic agent, in order to treat PTC-mediated injury in the subject.
[0123] In certain embodiments, immature stop codon-mediated disorders are those listed in Table 5 below, and / or genes having immature stop codons are those listed in the corresponding rows of Table 5 below.
[0124] [Table 5] TIFF2022554357000060.tif188128
[0125] In certain embodiments, immature stop codon-mediated disorders are those listed in Table 6 below, and / or genes having immature stop codons are those listed in the corresponding rows of Table 6 below.
[0126] [Table 6]
[0127] In a particular embodiment, the PTC-mediated disorder is epilepsy (e.g., Dravet syndrome), and the method reduces the frequency of seizures, the severity of seizures, and / or cognitive impairment in the subject. For example, in a particular embodiment, the method reduces the frequency of seizures in the subject by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% over a period of, for example, one day, one week, or one month. In a particular embodiment, the method reduces the severity of seizures by 50% over a period of, for example, one day, one week, or one month.
[0128] In certain embodiments, the PTC-mediated disorder is a drave and / or the gene having a premature stop codon is SCN1A. In certain embodiments, the premature stop codon within the SCN1A gene is c.5745C>G, c.5713G>T, c.5701C>T, c.5677C>T, c.5641C>T, c.5629C>T, c.5623C>T, c.5503A>T, c.5473G>T, c.5437G>T, c.5428C>T, c.5403G>A, c.5402G>A, c.5383G>T, c.5371G>T, c.5049T>G, c.4921G>T, c.4900C>T, c.4873C>T, c.4779del, c.4778G>A, c.4774G>T, c.4761T>G, c.4648G>T, c.4540C>T, c.4516A>T, c.4514C>A, c.4508T>G, c.4488C>G, c.4471G>T, c.4300A>T, c.4269G>A, c.4268G>A, c.4233T>A, c.4222G>T, c.4191G>A, c.4190G>A, c.4186C>T, c.4159A>T, c.4155C>A, c.3964del, c.3952C>T, c.3825G>A, c.3824G>A, c.3819G>A, c.3818G>A, c.3795T>A, c.3789T>G, c.3779G>A, c.3750C>G, c.3724G>T, c.3700C>T, c.3697C>T, c.3657dup, c.3624G>A, c.3604C>T, c.3582G>A, c.3578G>A, c.3574C>T, c.3463C>T, c.3454del, c.3424G>T, c.3422C>A, c.3406G>T, c.3328G>T, c.3273C>A, c.3262G>T, c.3073C>T, c.3060T>A, c.2844T>A, c.2749C>T, c.2695C>T, c.2645T>A, c.2560C>T, c.2551C>T, c.2541624C>T, c.1516C>T, c.1378C>T, c.1363C>T, c.1354A>T, c.1348C>T, c.1345G>T, c.1344dup, c.1306G>T, c.1278C>A, c.127 8C>G, c.1151G>A, c.1129C>T, c.1118T>A, c.942del, c.751del, c.644T>A, c.327C>G, c.249C>A, c.121A>T, c.4846_4850dup This is caused by a mutation or combination of mutations selected from c.4787_4788del, c.4578_4612dup, c.4211_4212del, c.4125_4130delinsATAATCATACTGATTGCCTAAAACTAAT, c.3690_3693del, c.3338_3339del, c.1247_1248insGTAGA, c.825_826insGTATA, and c.278_279dup. In certain embodiments, the premature stop codons within the SCN1A gene are c.58G>T, c.575G>A, c.664C>T, c.962C>G, c.1095dupT, c.1129C>T, c.1315C>T, c.1348C>T, c.13 66G>T, c.1492A>T, c.1537G>T, c.1624C>T, c.1738C>T, c.1804G>T, c.1837C>T, c.2134C>T, c.2370T>A, c.2495G>A, c.2593C>T, c.26 This is caused by a mutation or combination of mutations selected from 35delC, c.2904C>A, c.3295G>T, c.3311C>A, c.3452C>G, c.3637C>T, c.3656G>A, c.3733C>T, c.3783C>A, c.3829C>T, c.3985C>T, c.4359T>G, c.4547C>A, c.4573C>T, c.4721C>G, c.4954G>T, c.5641G>T, c.5656C>T, and c.5734C>T. In a particular aspect, immature stop codons within the SCN1A gene include c.664C>T, c.1129C>T, c.1492A>T, c.1624C>T, c.1738C>T, c.1837C>T, c.2134C>T, c.2593C>T, c.3637C>T, c.3733C>T, c.3985C>T, c.This is caused by mutations selected from 4573C>T, c.5656C>T, and c.5734C>T. In certain embodiments, the immature stop codon within the SCN1A gene is caused by mutations selected from c.1738C>T and c.3985C>T.
[0129] In certain embodiments, immature stop codons within the SCN1A gene are caused by the mutations shown in Table 7, or combinations of the mutations shown in Table 7.
[0130] [Table 7] TIFF2022554357000063.tif22678TIFF2022554357000064.tif131128
[0131] Further exemplary variants, including exemplary mutations that produce immature stop codons within genes, such as the SCN1A gene, can be found in ClinVar (available worldwide at ncbi.nlm.nih.gov / clinvar / ), “A catalog of SCN1A variants” Lossin et al. (2009) BRAIN DEV. 2009 31(2):114-30, the SCN1A Registry (available worldwide at scn1a.net / scn1a-registry / ), the SCN1A Mutation Database (available worldwide at gzneurosci.com / scn1adatabase), and the Leiden Open Variation Database (LOVD v.3.0; available worldwide at databases.lovd.nl / shared / genes / SCN1A). Unless otherwise indicated, all SCN1A mutations described herein are for SCN1a isoform 1 (NCBI reference sequence NM_001165963, SEQ ID NO:863).
[0132] In another aspect, the present invention provides a method for treating Dravet syndrome in subjects in need, wherein the subject has an SCN1A gene with a mutation shown in the row of Table 7, and the method comprises administering to the subject an effective amount of suppressor tRNA of the same suppressor class shown in the same row of Table 7 as the mutation, or an expression vector containing a nucleotide sequence encoding the tRNA. As used in Table 7, “suppressor class” (e.g., Arg>TGA) represents the type of endogenous tRNA from which the suppressor tRNA originates (e.g., arginine tRNA) and the stop codon recognized by the suppressor tRNA (e.g., TGA). An example Arg>TGA suppressor tRNA includes a tRNA containing a nucleotide sequence selected from SEQ ID NO: 6-9, 11, 16-18, 19-22, and 35. An example Gln>TAA suppressor tRNA includes a tRNA containing a nucleotide sequence selected from SEQ ID NO: 36-40, 44, and 45. The exemplary Gln>TAG suppressor tRNA contains a tRNA with a nucleotide sequence selected from SEQ ID NO: 178-182, 186, and 187.
[0133] For example, in a particular embodiment, the subject has an SCN1A gene having an immature stop codon selected from c.664C>T, c.3637C>T, c.3733C>T, c.2134C>T, and c.1837C>T, and the method comprises administering to the subject an effective amount of suppressor tRNA containing a nucleotide sequence selected from SEQ ID NO: 6-9, 11, 16-18, 19-22, and 35. In a particular embodiment, the subject has an SCN1A gene having an immature stop codon selected from c.3607C>T, c.2782C>T, c.3829C>T, and c.2893C>T, and the method comprises administering to the subject an effective amount of suppressor tRNA containing a nucleotide sequence selected from SEQ ID NO: 36-40, 44, and 45. In a particular embodiment, the subject has an SCN1A gene having an immature stop codon selected from c.3106C>T, c.3496C>T, c.5662C>T, c.5461C>T, and c.3730C>T, and the method comprises administering to the subject an effective amount of suppressor tRNA containing a nucleotide sequence selected from SEQ ID NO: 178-182, 186, and 187.
[0134] In a particular embodiment, where the gene is the SCN1A gene, the SCN1A gene product produced by tRNA is a functional SCN1A gene product. In a particular embodiment, the functional SCN1A gene product has higher activity than the truncated SCN1A gene product, for example, high voltage-opening sodium channel activity. In a particular embodiment, the method increases the voltage-opening sodium channel activity in cells, tissues, or subjects by approximately 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 250%, 300%, 350%, 400%, 450%, 500%, 600%, 700%, 800%, 900%, or 1000% compared to cells, tissues, or subjects without tRNA. In a particular embodiment, the method increases the voltage-opening sodium channel activity in cells, tissues, or subjects by approximately 20% to 200%, 20% to 180%, 20% to 160%, 20% to 140%, 20% to 120%, 20% to 100%, and 20% to 120%. Approximately 80%, approximately 20% to approximately 60%, approximately 20% to approximately 40%, approximately 40% to approximately 200%, approximately 40% to approximately 180%, approximately 40% to approximately 160%, approximately 40% to approximately 140%, approximately 40% to approximately 120%, approximately 40% to approximately 100%, approximately 40% to approximately 80%, approximately 40% to approximately 60%, approximately 60% to approximately 200%, approximately 60% to approximately 180%, approximately 60% to approximately 160%, approximately 60 %~approx. 140%, approx. 60%~approx. 120%, approx. 60%~approx. 100%, approx. 60%~approx. 80%, approx. 80%~approx. 200%, approx. 80%~approx. 180%, approx. 80%~approx. 160%, approx. 80%~approx. 140%, approx. 80%~approx. 120%, approx. 80%~approx. 100%, approx. 100%~approx. 200%, approx. 100%~approx. 180%, approx. 100%~approx. 160%, approx. 100% Increase by approximately 140%, 100% to 120%, 120% to 200%, 120% to 180%, 120% to 160%, 120% to 140%, 140% to 200%, 140% to 180%, 140% to 160%, 160% to 200%, 160% to 180%, or 180% to 200%.Potentially open sodium channel activity can be measured by any method known in the art, such as those described in Kalume et al. (2007) J. NEUROSCI. 27(41):11065-74, Yu et al. (2007) NAT. NEUROSCI. 9(9): 1142-9, and Han et al. (2012) NATURE 489(7416): 385-390.
[0135] In a particular manner, the functional SCN1A gene product is Na v 1.1 It is a protein. In a particular embodiment, a functional SCN1A gene product is essentially composed of, or consists of, an amino acid sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to any one of the following amino acid sequences: TIFF2022554357000065.tif95149TIFF2022554357000066.tif223149TIFF2022554357000067.tif223149 TIFF2022554357000068.tif229149TIFF2022554357000069.tif223149TIFF2022554357000070.tif177149
[0136] When used herein, the term "effective dose" refers to the amount of activator (e.g., tRNA or expression vector or a second activator in a combination therapy) sufficient to produce a beneficial or desired effect. The effective dose may be administered in one or more doses, applications, or prescriptions and is not intended to be limited to a specific formulation or route of administration.
[0137] As used herein, “treat,” “treating,” and “treatment” mean the treatment of a disease in a subject, for example, a human. This includes (a) suppressing the disease, i.e., stopping its progression; and (b) alleviating the disease, i.e., causing regression of the disease state. As used herein, the terms “subject” and “patient” refer to an organism treated by the methods and compositions described herein. Such organisms preferably include, but are not limited to, mammals (e.g., mice, monkeys, horses, cattle, pigs, dogs, cats, etc.), and more preferably include humans.
[0138] The methods and compositions described herein may be used alone or in combination with other therapeutic agents and / or modes of treatment. The term “administered in combination,” as used herein, is understood to mean that two (or more) different treatments are delivered to a subject while the subject is suffering from a disease, such that the effects of the treatments on the patient overlap at the time. In certain embodiments, the delivery of one treatment occurs even when the delivery of a second treatment has begun, resulting in an overlap in terms of administration. This is sometimes referred to herein as “simultaneous” or “concurrent delivery.” In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In certain embodiments of any example, the treatments are more effective because the administrations are combined. For example, the second treatment is more effective than it would be if it were administered in the absence of the first treatment, e.g., a smaller amount of the second treatment is equivalent in effect, or the second treatment reduces symptoms more significantly, or a similar situation is observed with the first treatment. In certain embodiments, the delivery is such that the reduction in symptoms or other parameters related to the disorder is greater than that observed when one treatment is delivered in the absence of the other. The effects of the two treatments may be partially additive, entirely additive, or more than additive. The delivery may be such that the effect of the first treatment being delivered is still detectable when the second treatment is delivered.
[0139] In certain embodiments, the methods or compositions described herein are administered in combination with one or more additional therapeutic agents, for example, DIACOMIT® (stiripentol), EPIODOLEX® (cannabidiol), a ketogenic diet, ONFI® (clobazam), TOPAMAX® (topiramate), fenfluramine, or valproic acid. For example, during the treatment of Dravet syndrome, the methods or compositions described herein are administered in combination with one or more additional therapeutic agents, for example, DIACOMIT® (stiripentol), EPIODOLEX® (cannabidiol), a ketogenic diet, ONFI® (clobazam), TOPAMAX® (topiramate), fenfluramine, or valproic acid.
[0140] Throughout the detailed descriptions in which a composition is described as having, including, or comprising a particular component, or in which a process and method is described as having, including, or comprising a particular step, it is assumed that there are compositions of the present invention that are essentially composed of or comprise the components mentioned, and that there are processes and methods according to the present invention that are essentially composed of or comprise the processes mentioned.
[0141] In examples where it is stated that an element or component is included in and / or selected from the list of elements or components mentioned, it should be understood that the element or component may be any one of the elements or components mentioned, or that the element or component may be selected from a group of two or more of the elements or components mentioned.
[0142] Furthermore, it should be understood that the elements and / or features of the compositions or methods described herein, whether expressly or implicitly, can be combined in various ways without departing from the spirit and scope of the invention. For example, where a reference is made to a particular compound, that compound can be used in various embodiments of the compositions of the invention and / or in the methods of the invention, unless otherwise understood from the context. In other words, while embodiments in this application are described and shown to describe and depict clear and concise examples, they are intended and will be understood to be able to be combined or separated in various ways without departing from the teachings and the invention. For example, it will be understood that all features described and shown herein may be applicable to all aspects of the invention described and shown herein.
[0143] The expression "at least one of ~" should be understood to include each individual object mentioned after the expression and various combinations of two or more of the objects mentioned, unless the context and usage indicate otherwise. The expression "and / or" in relation to three or more objects mentioned should also be understood to have the same meaning, unless the context indicates otherwise.
[0144] The use of the terms "include," "includes," "including," "have," "has," "having," "contain," "contains," and "containing," including their grammatical equivalents, should be understood to be generally open-ended and non-restrictive, for example, not excluding additional unmentioned elements or processes, unless specifically stated otherwise or understood from the context.
[0145] Where the term "approximately" is used before a quantity value, the present invention also includes that specific quantity value itself, unless otherwise specifically stated. As used herein, the term "approximately" represents a variation of ±10% from the stated value, unless otherwise indicated or inferred.
[0146] It should be understood that the order of the steps or the order in which certain actions are performed is not important, as long as the invention is feasible. Furthermore, two or more steps or actions may be performed simultaneously.
[0147] Any and all examples or illustrative terms used herein, such as “for example” or “including,” are intended solely to better illustrate the invention and do not impose any limitations on the scope of the invention unless otherwise stated in the claims. No term used herein should be construed as indicating any element not stated in the claims that is essential to the practice of the invention. [Examples]
[0148] The following examples are for illustrative purposes only and are not intended to limit the scope or content of the present invention in any way.
[0149] Example 1 This example describes an arginine aminoacylated suppressor tRNA that promotes read-through of immature stop codons (PTCs).
[0150] Suppressor tRNAs were created by converting endogenous mouse arginine-tRNAs to TCA anticodons that recognize TGA stop codons (Arg TCA (These are called suppressor tRNAs). Five of the endogenous arginine-tRNAs contained introns that had to be removed by splicing in order to produce mature tRNAs; corresponding Arg with and without these intron sequences.TCA Suppressor tRNA was prepared. The suppressor tRNA sequence is shown in Table 8.
[0151] [Table 8] TIFF2022554357000072.tif220154TIFF2022554357000073.tif226154TIFF2022554357000074.tif67154
[0152] In this example, all mature tRNA sequences (predicted by GtRNAdb; http: / / gtrnadb.ucsc.edu) were expressed in conjunction with upstream and downstream genomic flanking sequences (±200 bp) derived from the highly expressed arginine tRNA tRNA, tRNA-Arg-TCG-1-1. Specifically, the tRNA sequences were expressed together with the 5' flanking sequence of SEQ ID NO:26 and the 3' flanking sequence of SEQ ID NO:27. All mature tRNA sequences, including the upstream and downstream genomic flanking sequences, were generated within the pGL4 vector backbone.
[0153] This Arg TCASuppressors were tested for PTC readthrough activity by flow cytometry in cell lines containing a dual fluorescent readthrough reporter. These reporters contain three copies of red fluorescent protein (tdTomato), a TEV protease, a linker region containing PTC, and three copies of green fluorescent protein (EGFP). A schematic of the reporter construct is shown in Figure 3. In the absence of any PTC readthrough as a result of suppressor tRNA, translation will terminate at the PTC in the linker region, and only tdTomato will be expressed (thus only red fluorescence will be detected). PTC readthrough activity as a result of suppressor tRNA will allow translation to proceed through the PTC in the linker region, resulting in the expression of both tdTomato and EGFP (thus both red and green fluorescence will be detected). Therefore, readthrough can be assessed by quantifying the percentage of viable cells (dual-positive %) that express both red and green fluorescent reporters beyond the background.
[0154] To screen for suppressor tRNAs exhibiting readthrough activity in PTCs associated with Dravet syndrome, we generated PTCs and linker regions containing eight adjacent codons on either side of the PTC from the SCN1A transcripts of two patients, Subject N and Subject S, who had nonsense mutations in the SCN1A gene.
[0155] The linker region derived from the SCN1A transcript of target N is as follows, and the reporter containing this linker region is referred to as the target N-PTC reporter. A corresponding linker with a wild-type Arg codon was used as a control instead of TIFF2022554357000075.tif4147PTC, which had the following sequence: TIFF2022554357000076.tif4150
[0156] The linker region derived from the SCN1A transcript of target S is as follows, and the reporter containing this linker region is referred to as the target S-PTC reporter. TIFF2022554357000077.tif4147Instead of the PTC, the corresponding linker with a wild-type Arg codon was used as a control, which had the following sequence. TIFF2022554357000078.tif4150
[0157] An additional 51-base pair linker region was obtained from a mouse model of Dravet syndrome caused by the R1407X nonsense mutation in SCN1A (Ogiwara et al., 2007, Neurobiology of Disease). The linker region derived from the SCN1A R1407X transcript is as follows, and a reporter containing this linker region is referred to as the R1407X-PTC reporter. TIFF2022554357000079.tif4147Instead of the PTC, the corresponding linker with a wild-type Arg codon was used as a control, which had the following sequence. TIFF2022554357000080.tif4150
[0158] Arg TCA Suppressors were (i) human Flp-In-293 cell lines transiently transfected with a plasmid encoding the target S-PTC reporter and Arg [[ID=?]] TCA mouse Flp-In-3T3 cell lines transiently transfected with a plasmid encoding the R1407X-PTC reporter and Arg TCA (results shown in Figure 5), and (iii) Flp-In-293 cells transiently co-transfected with a plasmid encoding the target N-PTC reporter and a plasmid encoding the Arg TCA suppressor tRNA (results shown in Figure 6) in multiple assay settings. Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol.
[0159] It should be noted that there seems to be an incomplete or incorrect tag in the original text at line 18 which is marked as TCA in the original. I've translated as best as possible based on the available context.Further reporter constructs were created that include EGFP with a nuclear localization signal (NLS) and an arginine-to-TGA mutation (R96X) that causes fluorescence to disappear in the absence of PTC readthrough, within the EGFP open reading frame. A schematic of the experimental approach is shown in Figure 8A. EGFP expression was promoted by the CMV early enhancer / chicken β-actin (CAG) promoter. This reporter construct is called CAG:NLS-EGFP (R96X-TGA), and its sequence is as follows. TIFF2022554357000081.tif196149
[0160] Arg TCA In HEK293 cells and mouse Neuro-2a cells (a neural crest-derived cell line widely used to study neural differentiation) transiently co-transfected with a plasmid encoding suppressor tRNA and a plasmid encoding a CAG:NLS-EGFP (R96X-TGA) reporter, Arg TCA The activity of the suppressor was evaluated. Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol. Co-transfection was performed using equal amounts of the indicated suppressor plasmid and CAG:NLS-EGFP (R96X-TGA) reporter plasmid. EGFP expression was analyzed by flow cytometry approximately 24 hours after transfection in 293 cells and approximately 48 hours after transfection in Neuro-2a cells. The results are shown in Figure 7.
[0161] Generally, Arg TCAThe relative read-through activity of suppressor tRNAs remained consistent across multiple assay formats. The following suppressors reliably showed read-through activity above baseline: TCA-001 (SEQ ID NO: 11), TCA-89 (SEQ ID NO: 1), TCA-90 (SEQ ID NO: 2), TCA-105 (SEQ ID NO: 7), TCA-106 (SEQ ID NO: 8), TCA-107 (SEQ ID NO: 9), TCA-113 (SEQ ID NO: 16), TCA-114 (SEQ ID NO: 17), TCA-115 (SEQ ID NO: 18), TCA-116 (SEQ ID NO: 19), TCA-117 (SEQ ID NO: 20), TCA-118 (SEQ ID NO: 21), and TCA-119 (SEQ ID NO: 22).
[0162] In summary, these results indicate that the described suppressor tRNAs can promote the expression of transcripts containing immature stop codons associated with disorders, such as Dravet syndrome, e.g., the SCN1A transcript.
[0163] Example 2 This example describes the effect of expression vector characteristics on the read-through of immature stop codons (PTCs) by arginine aminoacylated suppressor tRNA.
[0164] Arg TCA Expression constructs containing both the suppressor tRNA and the EGFP (R96X-TGA) reporter on the same plasmid were prepared within the pGL4 vector backbone. These constructs contained 1, 2, 3, or 4 copies of Arg (as described in Example 1 and shown in Table 8). TCAIt contained suppressor tRNAs 113 (SEQ ID NO: 16), 115 (SEQ ID NO: 18), and 001 (SEQ ID NO: 11). Each copy of the tRNA sequence was expressed under one of the following sequence relationships: (i) a 200 bp upstream genomic facies sequence (SEQ ID NO: 26) derived from tRNA-Arg-TCG-1-1 and a 200 bp downstream genomic facies sequence (SEQ ID NO: 27) derived from tRNA-Arg-TCG-1-1 and a 200 bp downstream genomic facies sequence (SEQ ID NO: 27); (ii) a 200 bp upstream genomic facies sequence (SEQ ID NO: 26) derived from tRNA-Arg-TCG-1-1 and a 104 bp downstream genomic facies sequence (SEQ ID NO: 32) derived from tRNA-Arg-TCG-1-1; or (iii) an upstream U6 promoter containing a 19 bp upstream genomic facies sequence (SEQ ID NO: 33) derived from tRNA-Arg-TCG-1-1 and a 46 bp downstream genomic facies sequence (SEQ ID NO: 34) derived from tRNA-Arg-TCG-1-1. An outline of the experimental approach is shown in Figure 8A, and an outline of an exemplary reporter construct containing four copies of suppressor tRNA is shown in Figure 8B. The reporter construct was either a CAG:NLS-EGFP (R96X-TGA) reporter construct (described in Example 1) or an EF1a:NLS-EGFP (R96X-TGA) reporter construct in which the CAG promoter was replaced with an elongation factor 1 alpha (EF1a) promoter (the sequence of which is shown below). TIFF2022554357000082.tif208149
[0165] Neuro-2a cells or HEK293 (FlpIn-293) cells were transfected with these constructs, and readthrough assays were performed by fluorescence imaging or flow cytometry approximately 24 or 48 hours after transfection. Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol.
[0166] The results are shown in Figures 9-10 (fluorescence images) and Figures 11-17 (quantification of fluorescence signals measured by flow cytometry). For the 001 and 113 suppressors, improved readthrough was observed with increasing copy number. In summary, the results indicate that increasing the copy number of the suppressor tRNA module in the reporter construct often leads to improved readthrough activity. Furthermore, while the U6-containing construct showed PTC readthrough activity, it was generally not as active as that observed in equivalent suppressor tRNAs expressed in context with adjacent genomes.
[0167] Example 3 This example describes the design of a functional arginine aminoacylated suppressor tRNA that promotes readthrough of immature stop codons (PTCs) in transcripts.
[0168] C57BL / 6J mice have a spontaneously occurring C-to-T mutation in the T-loop (position 51) of Arg-TCT-5-1, which has been shown to affect pre-tRNA processing and function (Ryuta Ishimura et al., Science, 2014). (Described in Example 1 and shown in Table 8) Arg TCA Suppressor 120 includes T in 51st place. Arg TCA A modified suppressor tRNA was created containing a T-to-C substitution at position 51 of suppressor 120 (Arg TCA (It is called Suppressor 179 and has the nucleotide sequence SEQ ID NO:35). Arg TCA Suppressors 120 and 179 were tested by transfection into Flp-In-293 cell lines stably expressing the target S-PTC reporter, and by co-transfection into Flp-In-3T3 cells with a plasmid encoding the target N-PTC reporter. Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol. The results are shown in Figures 4 and 6. Arg TCASuppressor 120 is non-functional, whereas Arg contains only a single replacement. TCA Suppressor 179 showed PTC read-through activity.
[0169] Example 4 This example describes a glutamine aminoacylated suppressor tRNA that promotes read-through of immature stop codons (PTCs).
[0170] Suppressor tRNAs were created from endogenous mouse glutamine-tRNA by converting their normal anticodons to TTA or CTA anticodons (Gln, respectively). TTA Or Gln CTA (This is called suppressor tRNA.) The suppressor tRNA sequences are shown in Table 9.
[0171] [Table 9] TIFF2022554357000084.tif213154TIFF2022554357000085.tif213154TIFF2022554357000086.tif80154
[0172] In this example, all mature tRNA sequences were expressed in relation to upstream and downstream genomic flanking sequences (±200 bp) derived from tRNA-Gln-TTG-1-1, a highly expressed glutamine-tRNA; that is, the tRNA sequences were expressed together with the 5' flanking sequence of SEQ ID NO:173 and the 3' flanking sequence of SEQ ID NO:174. All mature tRNA sequences, including the upstream and downstream genomic flanking sequences, were constructed within the pGL4 vector backbone.
[0173] Gln TTAThe suppressor was tested for PTC readthrough activity by flow cytometry in two separately obtained Flp-In-293 cell lines containing the incorporated fluorescent readthrough reporter. The results are shown in Figure 18. The reporter contained three copies of red fluorescent protein (tdTomato), a TEV protease, a linker region containing PTC, and three copies of green fluorescent protein (EGFP). A schematic of the reporter construct is shown in Figure 3. In the absence of any PTC readthrough as a result of the suppressor tRNA, translation would terminate at the PTC in the linker region, and only tdTomato would be expressed (thus only red fluorescence would be detected). PTC readthrough activity as a result of the suppressor tRNA would allow translation to proceed through the PTC in the linker region, resulting in the expression of both tdTomato and EGFP (thus both red and green fluorescence would be detected). Therefore, readthrough can be assessed by quantifying the percentage of viable cells (double-positive %) expressing both red and green fluorescent reporters beyond the background using flow cytometry. The linker is mouse Dmd mdx The transcript was obtained and had the following sequence. Instead of TIFF2022554357000087.tif4149PTC, a corresponding linker with a wild-type Gln codon was used as a control, which had the following sequence: TIFF2022554357000088.tif4150
[0174] Further reporter constructs containing EGFP with a nuclear localization signal (NLS) and a glutamine-to-TAA mutation (Q69X) that eliminates fluorescence in the absence of PTC readthrough were constructed within the pGL4 vector backbone. EGFP expression was promoted by the CMV early enhancer / chicken β-actin (CAG) promoter. This reporter construct is referred to as CAG:NLS-EGFP (Q69X-TAA), and its sequence is as follows. TIFF2022554357000089.tif195149
[0175] Gln TTA Flow cytometry in Neuro-2a cells transiently co-transfected with a plasmid encoding suppressor tRNA and a plasmid encoding a CAG:NLS-EGFP (Q69X-TAA) reporter revealed that Gln TTA The activity of the suppressor was evaluated. Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol. The results are shown in Figure 19.
[0176] Further reporter constructs containing EGFP with a nuclear localization signal (NLS) and a glutamine-to-TAG mutation (Q69X) that eliminates fluorescence in the absence of PTC readthrough were constructed within the pGL4 vector backbone. EGFP expression was promoted by the CMV early enhancer / chicken β-actin (CAG) promoter. This reporter construct is referred to as CAG:NLS-EGFP (Q69X-TAG), and its sequence is as follows. TIFF2022554357000090.tif194149
[0177] Gln CTA In Neuro-2a cells transiently co-transfected with a plasmid encoding suppressor tRNA and a plasmid encoding a CAG:NLS-EGFP (Q69X-TAG) reporter, Gln CTA The activity of the suppressor was evaluated. The results are shown in Figure 20.
[0178] In summary, these results indicate that the described suppressor tRNAs can promote the expression of transcripts containing immature stop codons associated with the disorder.
[0179] Example 5 This example describes the readthrough activity of the disclosed suppressor tRNA and low-molecular-weight nonsense suppression therapy.
[0180] The disclosed suppressor tRNAs were tested with the nonsense inhibitors Translarna (Atarlen), gentamicin, and G418 (Geneticin). PTC readthrough activity was tested in Neuro-2a cells approximately 48 hours after transfection with an expression construct containing the CAG:NLS-EGFP (R96X-TGA) reporter (as described in Example 1), where (i) on the same construct, the indicated copy number of Arg TCA Neuro-2a cells were measured in which either (ii) were treated with suppressor tRNA, (iii) with gentamicin, or (iv) with G418. Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and at this point, the indicated drug was added at the indicated concentrations. PTC readthrough activity was measured as the percentage of EGFP-positive cells. A reporter containing wild-type EGFP without PTC was used as a control. Cell viability in cells treated with the above sets was evaluated by flow cytometry after staining with 7-aminoactinomycin D (7-AAD; Thermo Fisher Scientific #006993-50), a membrane-impermeable dye normally excluded from viable cells, according to the manufacturer's protocol. The results are shown in Figures 21-23. In summary, the results showed that Arg TCA The suppressor tRNA #115 (SEQ ID NO: 18) is shown to produce significantly more readthrough than any of the nonsense inhibitors. Furthermore, the results differ from those of any of the nonsense inhibitors, and Arg TCA Treatment with suppressor tRNA has been shown not to result in a decrease in cell viability.
[0181] Example 6 This example describes an aminoacylated suppressor tRNA that promotes read-through of immature stop codons (PTCs).
[0182] Suppressor tRNAs are created by converting endogenous mouse tRNAs from the normal anticodon to an anticodon that recognizes an immature stop codon (PTC). The suppressor tRNA sequences are shown in Table 10.
[0183] [Table 10] TIFF2022554357000092.tif199132TIFF2022554357000093.tif212132TIFF2022554357000094.tif226132 TIFF2022554357000095.tif220132TIFF2022554357000096.tif220132TIFF2022554357000097.tif220132 TIFF2022554357000098.tif206132TIFF2022554357000099.tif213132TIFF2022554357000100.tif213132 TIFF2022554357000101.tif213132TIFF2022554357000102.tif213132TIFF2022554357000103.tif213132 TIFF2022554357000104.tif213132TIFF2022554357000105.tif213132TIFF2022554357000106.tif220132 TIFF2022554357000107.tif220132TIFF2022554357000108.tif226132TIFF2022554357000109.tif213132 TIFF2022554357000110.tif213132TIFF2022554357000111.tif213132TIFF2022554357000112.tif226132 TIFF2022554357000113.tif220132TIFF2022554357000114.tif220132TIFF2022554357000115.tif100132
[0184] Suppressor tRNAs are tested for PTC readthrough activity by flow cytometry in cell lines containing a dual fluorescent readthrough reporter. These reporters contain three copies of red fluorescent protein (tdTomato), a TEV protease, a linker region containing PTC, and three copies of green fluorescent protein (EGFP). A schematic of the reporter construct is shown in Figure 3. In the absence of any PTC readthrough as a result of suppressor tRNA, translation will terminate at the PTC in the linker region, and only tdTomato will be expressed (thus only red fluorescence will be detected). PTC readthrough activity as a result of suppressor tRNA will allow translation to proceed through the PTC in the linker region, resulting in the expression of both tdTomato and EGFP (thus both red and green fluorescence will be detected). Therefore, readthrough can be assessed by quantifying the percentage of viable cells (dual-positive %) that express both red and green fluorescent reporters beyond the background.
[0185] Example 7 This example describes a glutamine aminoacylated suppressor tRNA that promotes read-through of immature stop codons (PTCs).
[0186] In this example, all mature tRNA sequences were expressed in relation to upstream and downstream genomic flanking sequences (±200 bp) derived from tRNA-Gln-TTG-1-1, a highly expressed glutamine tRNA. Specifically, the tRNA sequences were expressed using the 5' flanking sequence of SEQ ID NO:173 and the 3' flanking sequence of SEQ ID NO:174. All mature tRNA sequences, including the upstream and downstream genomic flanking sequences, were constructed within the pGL4 vector backbone.
[0187] Gln CTASuppressor tRNAs were tested for PTC readthrough activity by flow cytometry in Flp-In-293 cells either containing an integrated bifluorescent readthrough reporter or transiently co-transfected with an expression construct containing a bifluorescent readthrough reporter. These reporters contained three copies of red fluorescent protein (tdTomato), a TEV protease, a linker region containing PTC, and three copies of green fluorescent protein (EGFP). A schematic of the reporter construct is shown in Figure 3. In the absence of any PTC readthrough as a result of suppressor tRNA, translation would terminate at the PTC in the linker region, and only tdTomato would be expressed (thus only red fluorescence would be detected). PTC readthrough activity as a result of suppressor tRNA would allow translation to proceed through the PTC in the linker region, resulting in the expression of both tdTomato and EGFP (thus both red and green fluorescence would be detected). Therefore, readthrough was assessed by quantifying the percentage of viable cells expressing both red and green fluorescent reporters beyond the background (double-positive %) using flow cytometry. To screen for suppressor tRNAs exhibiting readthrough activity in PTCs associated with Dravet syndrome, we generated PTCs and linker regions containing eight adjacent codons on either side of the PTC from SCN1A transcripts of three patients with Gln(Q)-to-TAG nonsense mutations in SCN1A: Patient 3 (W1397X), Patient 4 (S1505X), and Patient 5 (Q1810X).
[0188] The linker region derived from the SCN1A transcript of patient 3 is as follows, and the reporter containing this linker region is referred to as the patient 3-Gln-TAG (W1397X) reporter. A corresponding linker with a wild-type Trp(W) codon was used as a control instead of TIFF2022554357000116.tif4149PTC, which had the following sequence: TIFF2022554357000117.tif4150
[0189] The linker region derived from the SCN1A transcript of patient 4 is as follows, and the reporter containing this linker region is referred to as the patient 4-Gln-TAG (S1505X) reporter. Instead of TIFF2022554357000118.tif4150PTC, a corresponding linker with wild-type Ser(S) was used as a control, which had the following sequence: TIFF2022554357000119.tif4150
[0190] The linker region derived from the SCN1A transcript of patient 5 is as follows, and the reporter containing this linker region is referred to as the patient 5-Gln-TAG (Q1810X) reporter. Instead of TIFF2022554357000120.tif4150PTC, a corresponding linker with a wild-type Gln codon was used as a control, which had the following sequence: TIFF2022554357000121.tif4150
[0191] Gln CTA Suppressor tRNAs (SEQ ID NO: 178~190) were used to (i) human Flp-In-293 cells transiently co-transfected with patient 3-Gln-TAG (W1397X) reporter, patient 4-Gln-TAG (S1505X) reporter, or patient 5-Gln-TAG (Q1810X) reporter (results shown in Figure 24), and (ii) cells that stably expressed patient 3-Gln-TAG (W1397X) reporter and Gln CTA PTC readthrough activity was tested by flow cytometry in multiple assay settings, including human Flp-In-293 cell lines transiently transfected with a plasmid encoding a suppressor tRNA (results shown in Figure 25). Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol.
[0192] In summary, these results indicate that the described suppressor tRNAs can promote the expression of transcripts containing immature stop codons associated with disorders, such as Dravet syndrome, e.g., the SCN1A transcript.
[0193] Example 8 This example describes the effect of nucleotide sequences adjacent to suppressor tRNA on the read-through of immature stop codons (PTCs) by suppressor tRNA.
[0194] EGFP-R96X-TGA reporter (as described in Example 1, SEQ ID NO: 31) and single copy of Arg TCA An expression vector encoding suppressor tRNA #115 (tRNA-Arg-TCT-2-1-TCA-SUP_without intron, SEQ ID NO:18, as described in Example 1) was constructed. This expression vector was obtained from genomic DNA located at the 5' and 3' ends of the mouse tRNA-Arg-TCG-1-1 gene in each example, but contained sequences of different lengths located immediately 5' and 3' ends of the tRNA coding sequence. Details of the expression vectors are shown in Table 11.
[0195] [Table 11]
[0196] The expression vectors in Table 11 were tested for PTC readthrough activity in Neuro-2a cells by flow cytometry. Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol. The results are shown in Figures 26A and 26B, where Arg TCA Suppressor tRNA #115 showed activity even with a random 5' leader sequence, but this study demonstrates that suppressor tRNA activity can be increased by using a 5' leader sequence derived from an endogenous tRNA gene.
[0197] Example 9 This example describes the effect of nucleotide sequences adjacent to suppressor tRNA on the read-through of immature stop codons (PTCs) by suppressor tRNA.
[0198] (i) In combination with one of 20 unique 100-nt leader sequences (sequences immediately 5' to the tRNA coding sequence) derived from human genomic DNA immediately 5' to an endogenous tRNA gene, and (ii) an expression vector library was prepared that contains a nucleotide sequence encoding TCA-115 (tRNA-Arg-TCT-2-1-TCA-SUP without intron, SEQ ID NO:18 as described in Example 1) or TTA-163 (tRNA-Gln-TTG-3-1-TTA-SUP, SEQ ID NO:45 as described in Example 4). A schematic diagram showing the design of the expression vector constructs of the library is shown in Figure 27. The 20 unique 100-nt leader sequences contain sequences derived from the most abundant tRNAs in human HEK293 cells and include leader sequences derived from the Arg-TCT-1-1 (SEQ ID NO:875), Tyr-GTA-5-1 (SEQ ID NO:883), Ser-GCT-3-1 (SEQ ID NO:878), Arg-TCG-1-1 (SEQ ID NO:886), Arg-TCG-3-1 (SEQ ID NO:888), Ser-TGA-1-1 (SEQ ID NO:879), Arg-TCG-5-1 (SEQ ID NO:871), Lys-TTT-6-1 (SEQ ID NO:887), Asn-GTT-1-1 (SEQ ID NO:880), Arg-CCG-2-1 (SEQ ID NO:877), Ala-AGC-4-1 (SEQ ID NO:874), Leu-TAA-1-1 (SEQ ID NO:876), Ser-CGA-4-1 (SEQ ID NO:870), Ser-TGA-4-1 (SEQ ID NO:869), Ser-GCT-2-1 (SEQ ID NO:872), Arg-TCT-2-1 (SEQ ID NO:881), Thr-TGT-1-1 (SEQ ID NO:885), Ile-AAT-4-1 (SEQ ID NO:873), Val-CAC-2-1 (SEQ ID NO:884), or Asn-GTT-3-1 (SEQ ID NO:882) genes.
[0199] These leader sequences and Arg TCA suppressor tRNA #115 (SEQ ID NO:18) or GlnTTA The combination of suppressor tRNA#163 (SEQ ID NO:45) with Arg TCA For constructs, PTC readthrough activity was tested by flow cytometry in cell lines co-transfected with the EGFP-R96X-TGA reporter (SEQ ID NO:31) or Gln TTA For constructs, the EGFP-Q69X-TAA reporter (SEQ ID NO:175). The results are shown in FIGS. 28-32 and show that (i) the activity of the suppressor tRNA is affected by the leader sequence and (ii) suppressor tRNAs (including different classes of suppressor tRNAs) show high readthrough activity when combined with the identified leader sequences.
[0200] Example 10 This example describes the readthrough activity of specific suppressor tRNAs and small molecule nonsense suppression therapies disclosed herein.
[0201] Suppressor tRNAs were tested with the nonsense inhibitors Translarna (Ataruren), gentamicin, and G418 (Geneticin). PTC readthrough activity was measured in Neuro-2a cells approximately 48 hours after transfection with an expression construct containing the CAG:NLS-EGFP (Q69X-TAA) reporter (described in Example 4, SEQ ID NO: 175), which were either (i) containing the indicated copy number of Gln suppressor tRNA (#002, tRNA-Gln-TTG-1-1-TTA-SUP, SEQ ID NO: 36, or #196, tRNA-Gln-TTG-1-1-CTA-SUP, SEQ ID NO: 178, both described in Example 4) on the same construct, or (ii) treated with Ataruren, (iii) treated with gentamicin, or (iv) treated with G418. Transfection was performed using Lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol. Under all experimental conditions, the cell culture medium was replaced with fresh medium approximately 6 hours after transfection, and the indicated drug was added at the indicated concentrations at this point. PTC readthrough activity was measured as the percentage of EGFP-positive cells by flow cytometry. A reporter containing wild-type EGFP without PTCs was used as a control. Cell viability in cells treated with the above set was evaluated by flow cytometry after staining with 7-aminoactinomycin D (7-AAD; Thermo Fisher Scientific #006993-50), a membrane-impermeable dye normally excluded from viable cells, according to the manufacturer's protocol. The results were then processed by Gln TTA For suppressor tRNA #002 (SEQ ID NO:36), see Figures 33-34, Gln CTAThe suppressor tRNA #196 (SEQ ID NO: 178) is shown in Figures 35-36. In summary, the results indicate that this suppressor tRNA produces more readthrough than any of the nonsense inhibitors. Furthermore, unlike any of the nonsense inhibitors, the results show that treatment with the suppressor tRNA does not result in a decrease in cell viability.
[0202] Example 11 This example describes the rescue of full-length SCN1a protein expression by a specific suppressor tRNA disclosed herein.
[0203] For Flp-In-293 cells, (i) an expression construct containing mouse SCN1A (SEQ ID NO: 899) having Arg(R)-to-TGA PTC (R1407X) and a C-terminal 3xFLAG tag peptide (DYKDHD-G-DYKDHD-I-DYKDDDDK) was transfected, and (ii) Arg TCA Expression constructs containing suppressor tRNA #115 (tRNA-Arg-TCT-2-1-TCA-SUP_intronless, SEQ ID NO:18) were co-transfected, or treated with G418, gentamicin, or atalurene. Expression constructs containing wild-type mouse SCN1A and a C-terminal 3xFLAG tag peptide (SEQ ID NO:898) were used as controls. SEQ ID NOs 898 and 899 are as follows: TIFF2022554357000123.tif42149TIFF2022554357000124.tif226149TIFF2022554357000125.tif226149TIFF20225543570 00126.tif227152TIFF2022554357000127.tif226149TIFF2022554357000128.tif226149TIFF2022554357000129.tif57149
[0204] SCN1A was detected by Western blotting as follows: 24 hours after transfection, the protein was isolated in RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific #89900) containing Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific #87786) according to the manufacturer's protocol. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific #23225). 30 μg of protein was separated on either NuPAGE 4-12% Bis-Tris (Thermo Fisher Scientific #NP0322BOX) or NuPAGE 3-8% Tris-Acetate (Thermo Fisher Scientific #EA0375BOX) protein gels at 150 V for 1.5 hours, then transferred to a PVDF membrane at 30 V overnight, followed by 250 mA at 4°C for 30 minutes. The blot was blocked in SuperBlock T20 Blocking Buffer (Thermo Fisher Scientific #37536) at room temperature for 1 hour, incubated overnight at 4°C in TBST with primary anti-FLAG M2 antibody (Sigma, F1804-200UG, 1:1000), washed three times with TBST, and incubated for 1 hour at room temperature with HRP secondary antibody (Thermo Fisher Scientific #31431, 1:30,000), a goat anti-mouse IgG(H+L) secondary antibody. This blot was developed by applying SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific #34094), and the signal was detected using the iBright imaging system. The results are shown in Figure 37, and Arg TCA This indicates that suppressor tRNA #115 was able to rescue full-length SCN1A protein expression, but small molecule drugs were not.
[0205] Furthermore, (i) an expression construct containing Arg(R)-to-TGA PTC (R1407X) and mouse SCN1A (SEQ ID NO:899) having a 3xFLAG tag at the C-terminus, and (ii) Arg TCA Suppressor tRNA #104 (tRNA-Arg-CCG-3-1-TCA-SUP, SEQ ID NO:6), Arg TCA Suppressor tRNA #106 (tRNA-Arg-CCT-2-1-TCA-SUP, SEQ ID NO:8) or Arg TCA An expression construct containing suppressor tRNA #115 (tRNA-Arg-TCT-2-1-TCA-SUP_intron-free, SEQ ID NO:18) was co-transfected into Flp-In-293 cells. SCN1A expression was measured by Western blotting using an anti-FLAG antibody as described above in this example. The results are shown in Figure 38, indicating that each suppressor tRNA tested rescued full-length SCN1A protein expression.
[0206] In addition, (i) an expression construct containing Arg(R)-to-TGA PTC (R1407X) and mouse SCN1A (SEQ ID NO: 899) with a 3xFLAG tag at the C-terminus, and (ii) Arg in various doses (13 ng per well, 40 ng per well, 113 ng per well, or 400 ng per well; 6-well cell culture plate). TCA An expression construct containing suppressor tRNA#115 (tRNA-Arg-TCT-2-1-TCA-SUP_intron-free, SEQ ID NO:18) was co-transfected into Flp-In-293 cells. SCN1A expression was measured by Western blotting using an anti-FLAG antibody as described above in this example. The results are shown in Figure 39, demonstrating that tRNA 115 was able to rescue full-length SCN1A protein expression over a wide dose range.
[0207] Example 12 This example describes the read-through activity of the disclosed suppressor tRNA delivered by an adeno-associated virus (AAV) vector.
[0208] The constructs packaged in the AAV-PHP.eB capsid are shown in Figure 40. Construct 262 contains wild-type EGFP promoted by the EF1a promoter. Construct 269 contains EGFP-R96X-TGA (SEQ ID NO: 177) and two copies of Arg, promoted by the EF1a promoter under the context of a 55 bp upstream adjacent genomic DNA (SEQ ID NO: 900) derived from tRNA-Tyr-GTA-5-1. TCA The constructs contain suppressor tRNA #115 (tRNA-Arg-TCT-2-1-TCA-SUP_intron-free, SEQ ID NO:18, as described in Example 1). Both constructs contain 5' and 3' ITR sequences derived from AAV2 that provide cis-active elements for AAV replication and packaging. AAV-PHP.eB, containing constructs 262 and 269, was generated by Vigene Biosciences.
[0209] Prior to AAV transduction, 293 cells (Agilent #240073) were pre-transfected with an expression construct containing the LY6A gene (CCDS ID 27540.1), which is promoted by the CMV early enhancer / chicken β-actin (CAG) promoter necessary for reliable transduction by AAV-PHP.eB. For pre-transfection, cells were transiently transfected with the LY6A expression construct using lipofectamine 3000 Transfection Reagent according to the manufacturer's protocol. Approximately 24 hours after transfection, the medium was replaced with fresh medium, and the cells were allowed to recover for another 24 hours before viral transduction. The cells were then transduced at an MOI of 1E5 vg / cell. The results are shown in Figure 41. Arg delivered by AAV TCASuppressor tRNA #115 achieved approximately 13.2% PTC readthrough based on GFP intensity. The suppressor tRNA exhibits comparable readthrough activity when delivered via AAV or transient transfection.
[0210] Example 13 This example describes a ribosome profiling experiment demonstrating that the disclosed suppressor tRNA does not induce a significant amount of off-target native stop codon readthrough.
[0211] To determine whether suppressor tRNA induces native stop codon readthrough, ribosome profiling was used to quantify (i) the number of ribosomes found in the 3' UTR of mRNA from cells transfected with an expression construct containing suppressor tRNA, and (ii) the number of ribosomes found in cells transfected with an expression construct lacking suppressor tRNA. Ribosomes typically terminate translation when they encounter a stop codon. Therefore, if suppressor tRNA increases native stop codon readthrough, this would be indicated by an increase in ribosome density found in the 3' UTR of mRNA in cells expressing suppressor tRNA, particularly in 3' UTR mRNA containing the native stop codon recognized by the expressed suppressor tRNA.
[0212] Neuro-2a cells have (i) the same construct on which the EGFP-R96X-TGA reporter (SEQ ID NO:177) and Arg TCACells were transfected with either (ii) an expression construct containing suppressor tRNA #001 (SEQ ID NO:11) or (ii) an expression construct lacking suppressor tRNA and containing a wild-type version of the EGFP reporter. EGFP expression is shown in Figure 42. Approximately 48 hours after transfection, cells were subjected to ribosome footprint profiling as follows: Cells were lysed in lysis buffer (10 mM Tris-HCl pH 7.5, 5 mM MgCl2, 100 mM KCl, 1% Triton X-100, 1 mM DTT, 50 μg / mL Emetine (Sigma #324693), and 500 U / mL RNAsin (Promega #N2615)), the cell lysates were sheared 10 times using a 25 gauge needle, and then centrifuged at 20,000 g for 10 minutes at 4°C. The supernatant was digested with micrococcal nuclease (MNase; 120 units / OD A260 lysate; New England Biolabs #M0247S) at room temperature for 30 minutes, after which the reaction was stopped by adding 5 μL of SuperAse-IN (Thermo Fisher Scientific #AM2694). The MNase-treated extracts were subjected to a 15–45% sucrose gradient and separated by density using an SW 41Ti swing bucket rotor (Beckman Coulter #331362) at 41,000 rpm and 4°C for 2:26 hours. After collection of fractions and monosome-containing fractions, ribosome-protected mRNA fragments were precipitated from sucrose overnight at -20°C using 1.25 mL of 95% ethanol. mRNA fragments were resuspended in 10 mM Tris-HCl, pH 8.0, and separated on a 15% denatured polyacrylamide gel (TBE-urea gel; Thermo Fisher Scientific #EC68852BOX). RNA fragments with sizes ranging from 26 to 34 nt were excised from the gel and isolated to produce a ribosome-protected fragment library.Following 3' linker ligation, rRNA removal using Ribo-Zero reagent from the TruSeq Stranded Total RNA Library Prep Gold Kit (Illumina #20020598), reverse transcription, cyclization, and PCR amplification with index primers, the PCR products were separated on an 8% non-denaturing polyacrylamide gel (Thermo Fisher Scientific #EC62152BOX). The barcoded cDNA library was extracted from the gel and sequenced using a NextSeq 550 sequencing system in a single-read-run manner. After sequencing, adapters were excised from the raw reads using Trimmomatic, and non-coding RNAs were removed by alignment to the Ensembl mouse mm10 ncRNA reference using bowtie2. The remaining reads were aligned to the UCSC mm10 mouse reference assembly, again using bowtie2. Duplicately mapped reads were discarded. The final set of aligned reads was quantified using the RiboProfiling package in R and a custom Python script. Using Python, we created plots to test the 3' UTR occupancy and change ratio for each gene with 20 or more uniquely mapped reads, and compared the distribution of genes with each native stop codon using the two-sample Kolmogorov-Smirnov test. The results are shown in Figure 43.
[0213] In summary, these results indicate that suppressor tRNAs can promote the expression of transcripts containing immature stop codons, such as EGFP-R96X-TGA, without causing significant read-through of off-target native stop codons in the cells expressing them.
[0214] Inclusion by reference For all purposes, the full disclosures of each patent and scientific document cited herein are incorporated by reference.
[0215] Equivalents The present invention may be embodied in other specific forms without departing from its spirit or essential features. Therefore, the above embodiments should be considered in all respects as illustrative rather than limiting to the invention described herein. Accordingly, the scope of the invention is indicated not by the above detailed description but by the appended claims, and all modifications made within the object and equivalent scope of the claimed invention are intended to be incorporated into the present invention.
Claims
1. A tRNA encoded by a nucleotide sequence selected from SEQ ID NOs: 39, 181, 19-21, 40, 179, 182, and 186, or a sequence comprising a nucleotide sequence set forth in Table 2.
2. a) contain naturally occurring nucleotide modifications, and / or b) comprising one or more nucleotide modifications selected from 5-methyluridine, 5-carbamoylmethyluridine, 5-carbamoyl-methyl-2-O-methyluridine, 5-methoxy-carbonylmethyluridine, 5-methoxycarbonylmethyl-2-thiouridine, pseudouridine, dihydrouridine, 1-methyladenosine, and inosine; The tRNA of claim 1.
3. An expression vector comprising a nucleotide sequence encoding the tRNA of claim 1 or 2.
4. a) comprising one, two, three, four, or more than four copies of a nucleotide sequence encoding said tRNA; b) comprising a nucleotide sequence selected from SEQ ID NOs: 869-888; and / or c) comprising the nucleotide sequence shown in Table 4; The expression vector of claim 3.
5. An expression vector comprising a nucleotide sequence selected from SEQ ID NOs: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187, or a tRNA as set forth in Table 3, wherein the expression vector comprises one, two, three, four, or more than four copies of the nucleotide sequence encoding the tRNA.
6. 6. The expression vector of claim 5, comprising a nucleotide sequence selected from SEQ ID NOs:869-888, or a nucleotide sequence as set forth in Table 4.
7. 6. The expression vector of claim 3 or 5, which is a viral vector.
8. a) the viral vector is a DNA viral vector; and / or b) the viral vector is an adeno-associated viral (AAV) vector; The expression vector of claim 7.
9. A pharmaceutical composition comprising the tRNA of claim 1 or 2 or the expression vector of claim 3 or 5, and a pharma- ceutically acceptable excipient.
10. a) the tRNA or expression vector is not conjugated or attached to another moiety or carrier particle; and / or b) the pharmaceutical composition does not contain nanoparticles and / or does not contain an aminolipid delivery compound; 10. The pharmaceutical composition of claim 9.
11. 1. A pharmaceutical composition for expressing in a mammalian cell a functional gene product encoded by a gene containing a premature termination codon, comprising: A pharmaceutical composition comprising an effective amount of a tRNA of claim 1 or 2 or a tRNA shown in Table 3, or an expression vector of claim 3 or 5 or an expression vector comprising a nucleotide sequence encoding a tRNA shown in Table 3, which allows for the incorporation of an amino acid into a gene product at a position that would otherwise result in a truncated gene product due to a premature stop codon.
12. a) the cell contains less truncated gene product than a cell not having the tRNA; b) the cell contains a greater amount of a functional gene product than a cell not having the tRNA; c) the gene is a gene shown in Table 5 or Table 6; d) the tRNA comprises a nucleotide sequence selected from SEQ ID NOs: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187; e) the gene containing the premature termination codon is the dystrophin gene; and / or f) the gene containing the premature termination codon is the SCN1A gene; 12. The pharmaceutical composition of claim 11.
13. A pharmaceutical composition for increasing in a cell a voltage-gated sodium channel activity encoded by an SCN1A gene containing a premature stop codon, comprising: A pharmaceutical composition comprising an effective amount of a tRNA of claim 1 or 2 or a tRNA shown in Table 3, or an expression vector of claim 3 or 5 or an expression vector comprising a nucleotide sequence encoding a tRNA shown in Table 3, which allows an amino acid to be incorporated into the SCN1A gene product at a position where a truncated SCN1A gene product would otherwise result due to a premature stop codon.
14. The pharmaceutical composition of claim 13, wherein the tRNA comprises a nucleotide sequence selected from SEQ ID NOs: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, and 187.
15. a) the SCN1A gene product produced by said tRNA is a functional SCN1A gene product comprising any one of SEQ ID NOs:863-868; and / or b) a premature stop codon in the SCN1A gene is caused by a mutation selected from c.664C>T, c.1129C>T, c.1492A>T, c.1624C>T, c.1738C>T, c.1837C>T, c.2134C>T, c.2593C>T, c.3637C>T, c.3733C>T, c.3985C>T, c.4573C>T, c.5656C>T, and c.5734C>T; 13. The pharmaceutical composition of claim 12.
16. a) the functional SCN1A gene product has greater activity than a truncated SCN1A gene product; and / or b) The functional SCN1A gene product is v 1.1 Protein, 16. The pharmaceutical composition of claim 15.
17. The pharmaceutical composition of claim 11, wherein the cell is a human cell.
18. A pharmaceutical composition for treating a premature stop codon mediated disorder in a subject in need thereof, comprising an effective amount of a tRNA of claim 1 or 2, or a tRNA shown in Table 3 or Table 10, or an expression vector of claim 3 or 5, or an expression vector comprising a nucleotide sequence encoding a tRNA shown in Table 3 or Table 10.
19. a) the gene is a gene shown in Table 5 or Table 6; b) the premature stop codon mediated disorder is Duchenne muscular dystrophy or Dravet syndrome, and / or a disorder shown in Table 5 or Table 6, and / or c) the tRNA comprises a nucleotide sequence selected from SEQ ID NOs: 6-9, 11, 16-18, 22, 35, 36, 38, 45, 178, 180, 187, 233, 420, 426, 447, 451, 457, 500, 511, 517, 521, 683, 684, and 690; 19. The pharmaceutical composition of claim 18.
20. 20. The pharmaceutical composition of claim 19, further comprising stiripentol, cannabidiol, a ketogenic diet, clobazam, topiramate, fenfluramine, or valproic acid.
21. 20. The pharmaceutical composition of claim 18, wherein the subject is a human.
